

4-18-2023

The Global Fatty Liver Disease-Sustainable Development Goal Country Score for 195 Countries and Territories

Jeffrey V. Lazarus

Hannah Han

Henry E. Mark

Saleh A. Schattenberg

Jörn M. J.

See next page for additional authors

Follow this and additional works at: https://scholarcommons.sc.edu/phar_facpub



Part of the [Pharmacy and Pharmaceutical Sciences Commons](#)

Publication Info

Postprint version. Published in *Hepatology*, 2023.

© 2023 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the [Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 \(CCBY-NC-ND\)](#), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

This Article is brought to you by the Pharmacy, College of at Scholar Commons. It has been accepted for inclusion in Faculty Publications by an authorized administrator of Scholar Commons. For more information, please contact digres@mailbox.sc.edu.

Author(s)

Jeffrey V. Lazarus, Hannah Han, Henry E. Mark, Saleh A. Schattenberg, Jörn M. J., Ismaeel Yunusa Ph. D., and Et Al.

The global Fatty Liver Disease-Sustainable Development Goal country score for 195 countries and territories

Jeffrey V Lazarus, PhD,^{1,2,3,4} Hannah Han, MSc,⁵ Henry E Mark, MBA,⁶ Saleh A Alqahtani, MD,⁷ Jörn M J Schattenberg, MD,⁸ Joan B Soriano, MD,^{9,10} Trenton Michael White, MPH,¹¹ Shira Zelber-Sagi, PhD,^{12,13} Amirali Aali, MD,¹⁴ Mohsen Abbasi-Kangevari, MD,¹⁵ Eman Abu-Gharbieh, PhD,¹⁶ Osama Abu-Shawar, MD,¹⁷ Manik Aggarwal, MD,¹⁷ Bright Opoku Ahinkorah, MPhil,¹⁸ Aqeel Ahmad, PhD,¹⁹ Ali Ahmadi, PhD,^{20,21} Fares Alahdab, MSc,²² Motasem Alkhayyat, MD,¹⁷ Sami Almustanyir, MD,^{23,24} Hubert Amu, PhD,²⁵ Amir Anoushiravani, MD,²⁶ Tahira Ashraf, MS,²⁷ Bantalem Tilaye Tilaye Atinafu, MSc,²⁸ Sina Azadnajafabad, MD,¹⁵ Nayereh Baghcheghi, PhD,²⁹ Sara Bagherieh, BSc,³⁰ Mainak Bardhan, MD,^{31,32} Diana Fernanda Bejarano Ramirez, BN,^{33,34} Akshaya Srikanth Bhagavathula, PhD,³⁵ Neeraj Bhala, PhD,^{36,37} Ajay Nagesh Bhat, MD,³⁸ Mariah Malak Bilalaga, MBBS,³⁹ Antonio Biondi, PhD,⁴⁰ Saeid Bitaraf, PhD,⁴¹ Srinivasa Rao Bolla, PhD,⁴² Antoine Boustany, MD,¹⁷ Daniela Calina, PhD,⁴³ Ismael R Campos-Nonato, PhD,⁴⁴ Vijay Kumar Chattu, MD,^{45,46} Sheng-Chia Chung, PhD,^{47,48} Daniela Contreras, MD,⁴⁹ Sandra Cortés, DrPH,^{50,51} Omar B Da'ar, PhD,⁵² Omid Dadras, DrPH,^{53,54} Xiaochen Dai, PhD,^{5,55} Bardia Danaei, MD,⁵⁶ Rupak Desai, MBBS,⁵⁷ Shirin Djalalinia, PhD,⁵⁸ Deepa Dongarwar, MS,⁵⁹ Haneil Larson Dsouza, MD,^{60,61} Temitope Cyrus Ekundayo, PhD,⁶² Iman El Sayed, PhD,⁶³ Noha Mousaad Elemam, PhD,⁶⁴ Mohamed A Elmonem, PhD,⁶⁵ Aisha Elsharkawy, MD,⁶⁶ Sayeh Ezzikouri, PhD,⁶⁷ Amr Farwati, MD,⁶⁸ Farshad Farzadfar, DSc,¹⁵ Ginenus Fekadu, MSc,^{69,70} Florian Fischer, PhD,⁷¹ Tushar Garg, MBBS,⁷² Elena S George, PhD,⁷³ Seyyed-Hadi Ghamari, MD,^{15,74} Mohammad Ghasemi Nour, MD,⁷⁵ Amit Goel, DM,⁷⁶ Mahaveer Golechha, PhD,⁷⁷ Pouya Goleij, MSc,⁷⁸ Vivek Kumar Gupta, PhD,⁷⁹ Parham Habibzadeh, MD,⁸⁰ Adel Hajj Ali, MD,⁸¹ Saeed S Hamid, MD,⁸² Harapan Harapan, PhD,⁸³ Sanam Hariri, MD,^{26,84} Maryam Hashemian, PhD,^{85,26} Abbas M Hassan, MD,⁸⁶ Mohammed Bheser Hassen, BSc,^{5,87} Simon I Hay, FMedSci,^{5,88} Yuta Hiraike, PhD,⁸⁹ Reza Homayounfar, PhD,^{90,91} Mohammad-Salar Hosseini, MD,⁹² Sedighe Hosseini Shabanan, MD,⁹³ Soodabeh Hoveidamanesh, MD,⁹⁴ Vivian Chia-rong Hsieh, PhD,⁹⁵ Junjie Huang, MD,⁹⁶ Salman Hussain, PhD,^{97,98} Segun Emmanuel Ibitoye, MPH,⁹⁹ Olayinka Stephen Ilesanmi, PhD,^{100,101} Nahlah Elkudssiah Ismail, PhD,¹⁰² Chidozie C D Iwu, MPH,¹⁰³ Linda Merin J, BDS,¹⁰⁴ Elham Jamshidi, PharmD,^{105,106} Umesh Jayarajah, MD,^{107,108} Shubha Jayaram, MD,¹⁰⁹ Bijay Mukesh Jeswani, MBBS,¹¹⁰ Jost B Jonas, MD,^{111,112} Abel Joseph, MD,¹⁷ Charity Ehimwenma Joshua, BSc,¹¹³ Jacek Jerzy Jozwiak, PhD,¹¹⁴ Ali Kabir, MD,¹¹⁵ Vidya Kadashetti, MDS,¹¹⁶ Tesfaye K Kanko, MSc,¹¹⁷ Rami S Kantar, MD,^{118,119} Nitin Kapoor, PhD,^{120,121} Ibraheem M Karaye, MD,¹²² Joonas H Kauppila, MD,^{123,124} Mohammad Keykhai, MD,^{15,125} Moien AB Khan, MSc,^{126,127} Min Seo Kim, MD,^{128,129} Hamid Reza Koohestani, PhD,¹³⁰ Ambily Kuttikkattu, MD,¹³¹ Carlo La Vecchia, MD,¹³² Bagher Larijani, FACE,¹³³ Sang-woong Lee, PhD,¹³⁴ Yeong Yeh Lee, PhD,^{135,136} Lee-Ling Lim, MRCP,^{137,138} Stephen S Lim, PhD,^{5,55} Chun-Han Lo, MD,¹³⁹ Stefan Lorkowski, PhD,^{140,141} Jamal Majidpoor, PhD,¹⁴² Mohammad-Reza Malekpour, MD,¹⁵

Yasaman Mansoori, MD,¹⁴³ Miquel Martorell, PhD,^{144,145} Sahar Masoudi, MSc,²⁶ Alexios-Fotios A Mentis, MD,¹⁴⁶ Tuomo J Meretoja, MD,^{147,148} Tomislav Mestrovic, PhD,^{149,5} Erkin M Mirrahimov, PhD,^{150,151} Awoke Misganaw, PhD,^{88,152} Abdollah Mohammadian-Hafshejani, PhD,²⁰ Ali H Mokdad, PhD,^{5,88} Jibrán Sualeh Muhammad, PhD,¹⁵³ Efrén Murillo-Zamora, PhD,^{154,155} Christopher J L Murray, DPhil,^{5,55} Mukhammad David Naimzada, MD,^{156,157} Sreenivas Narasimha Swamy, MD,¹⁵⁸ Hasan Nassereldine, MD,⁵ Zuhair S Natto, DrPH,^{159,160} Robina Khan Niazi, PhD,¹⁶¹ Virginia Nuñez-Samudio, PhD,^{162,163} Bogdan Oancea, PhD,¹⁶⁴ In-Hwan Oh, PhD,¹⁶⁵ Olubunmi Omotola Oladunjoye, MD,¹⁶⁶ Antonio Olivas-Martinez, MD,^{167,168} Jagadish Rao Padubidri, MD,¹⁶⁹ Seoyeon Park, Beng,¹⁷⁰ Harsh K Patel, MD,¹⁷¹ Ronit Patnaik Patnaik, MD,¹⁷² Venkata Suresh Pathipati, MD,^{173,174} Gayatri Pemmasani, MD,¹⁷⁵ Simone Perna, PhD,¹⁷⁶ Vivek Podder, HSC,^{177,178} Akram Pourshams, MD,²⁶ Akila Prashant, PhD,¹⁷⁹ Pradhum Ram, MD,¹⁸⁰ Indu Ramachandra Rao, DM,¹⁸¹ Sina Rashedi, MD,^{182,183} Mohammad-Mahdi Rashidi, MD,^{15,74} Negar Rezaei, PhD,^{15,133} Jefferson Antonio Buendia Rodriguez, PhD,¹⁸⁴ Leonardo Roever, PhD,¹⁸⁵ Gholamreza Roshandel, PhD,¹⁸⁶ Bahar Saberzadeh-Ardestani, MD,¹⁸⁷ Umar Saeed, PhD,^{188,189} Sher Zaman Safi, PhD,^{190,191} Amirhossein Sahebkar, PhD,^{192,193} Soumya Swaroop Sahoo, MD,¹⁹⁴ Mohammad Amin Salehi, MD,¹⁹⁵ Abdallah M Samy, PhD,^{196,197} Senthilkumar Sankararaman, MD,^{198,199} Chinmoy Sarkar, PhD,²⁰⁰ Danish Iltaf Satti, MD,²⁰¹ Allen Seylani, BS,²⁰² Pritik A Shah, MBBS,^{203,204} Elaheh Shaker, MD,^{183,205} Ali Shamekh, MD,^{206,207} Parnian Shobeiri, MD,^{208,205} Seyed Afshin Shorofi, PhD,^{209,210} Jasvinder A Singh, MD,^{211,212} Paramdeep Singh, MD,²¹³ Md Shahjahan Siraj, MSc,²¹⁴ Anna Aleksandrovna Skryabina, MD,²¹⁵ Amir Ali Sohrabpour, MD,²⁶ Keita Suzuki, PhD,²¹⁶ Majid Taheri, PhD,^{217,218} Ker-Kan Tan, PhD,²¹⁹ Samar Tharwat, MD,²²⁰ Nikhil Kenny Thomas, MD,²²¹ Bereket M Tigabu, PhD,²²² Marco Vacante, PhD,⁴⁰ Seyed Mohammad Vahabi, MD,¹⁹⁵ Rohollah Valizadeh, PhD,²²³ Tommi Juhani Vasankari, MD,^{224,225} Theo Vos, PhD,^{5,55} Cong Wang, MPH,²²⁶ Song Wang, PhD,²²⁷ Nuwan Darshana Wickramasinghe, MD,²²⁸ Suowen Xu, PhD,^{229,230} Chuanhua Yu, PhD,²³¹ Ismaeel Yunusa, PhD,²³² Mazyar Zahir, MD,²³³ Moein Zangiabadian, MD,²³⁴ Zhi-Jiang Zhang, PhD,²³⁵ M Ashworth Dirac, MD.^{5,55,236}

, on behalf of the GBD Fatty Liver Disease-SDG Collaborators

[AU: All group members who meet the criteria for authorship must be named in the text so that they can be indexed in PubMed. Please check and confirm that these are ok.]

¹Barcelona Institute for Global Health, Barcelona, Spain

²EASL International Liver Foundation, Geneva, Switzerland

³Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain

⁴CUNY Graduate School of Public Health and Health Policy, City University of New York, New York, NY, USA

⁵Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA

⁶EASL International Liver Foundation, Geneva, Switzerland,

⁷Organ Transplant Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia,

⁸Metabolic Liver Research Program, I. Department of Medicine, University Medical Center Mainz, Mainz, Germany,

⁹Hospital Universitario de La Princesa (Princess University Hospital), Autonomous University of Madrid, Madrid, Spain

¹⁰Centro de Investigación Biomédica en Red Enfermedades Respiratorias (Center for Biomedical Research in Respiratory Diseases Network), Madrid, Spain

¹¹Health Systems and Infectious Disease Team, Barcelona Institute for Global Health, Barcelona, Spain

- ¹²School of Public Health, University of Haifa, Haifa, Israel
- ¹³Department of Gastroenterology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
- ¹⁴Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
- ¹⁵Non-communicable Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran
- ¹⁶Clinical Sciences Department, University of Sharjah, Sharjah, United Arab Emirates
- ¹⁷Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA
- ¹⁸School of Public Health, University of Technology Sydney, Sydney, NSW, Australia
- ¹⁹Department of Medical Biochemistry, Shaqra University, Shaqra, Saudi Arabia
- ²⁰Department of Epidemiology and Biostatistics, Shahrekord University of Medical Sciences, Shahrekord, Iran
- ²¹Department of Epidemiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- ²²Mayo Evidence-based Practice Center, Mayo Clinic Foundation for Medical Education and Research, Rochester, MN, USA
- ²³College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
- ²⁴Ministry of Health, Riyadh, Saudi Arabia
- ²⁵Department of Population and Behavioural Sciences, University of Health and Allied Sciences, Ho, Ghana
- ²⁶Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
- ²⁷University Institute of Radiological Sciences and Medical Imaging Technology, The University of Lahore, Lahore, Pakistan
- ²⁸School of Nursing and Midwifery Science, Debre Berhan University, Debre Berhan, Ethiopia
- ²⁹Nursing, Saveh University of Medical Sciences, saveh, Iran
- ³⁰School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
- ³¹Department of Molecular Microbiology and Bacteriology, National Institute of Cholera and Enteric Diseases, Kolkata, India
- ³²Department of Molecular Microbiology, Indian Council of Medical Research, New Delhi, India
- ³³Department of Medicine, El Bosque University, Bogota, Colombia
- ³⁴Transplant Service Unit, University Hospital Foundation Santa Fe de Bogotá, Bogota, Colombia
- ³⁵Department of Health, Human Performance and Recreation, University of Arkansas, Fayetteville, AR, USA
- ³⁶Institutes of Applied Health Research and Translational Medicine, Queen Elizabeth Hospital Birmingham, Birmingham, UK
- ³⁷Institute of Applied Health Research, University of Birmingham, Birmingham, UK
- ³⁸Department of General Medicine, Manipal Academy of Higher Education, MANGALORE, India
- ³⁹Department of Clinical Sciences, University of Sharjah, Sharjah, United Arab Emirates
- ⁴⁰Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy
- ⁴¹Department of Biostatistics and Epidemiology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
- ⁴²Department of Biomedical Sciences, Nazarbayev University, Nur-Sultan City, Kazakhstan
- ⁴³Department of Clinical Pharmacy, University of Medicine and Pharmacy, Craiova, Romania
- ⁴⁴Health and Nutrition Research Center, National Institute of Public Health, Cuernavaca, Mexico
- ⁴⁵Department of Community Medicine, Datta Meghe Institute of Medical Sciences, Sawangi, India
- ⁴⁶Saveetha Medical College and Hospitals, Saveetha University, Chennai, India

- ⁴⁷Department of Health Informatics, University College London, London, UK
- ⁴⁸Health Data Research UK, London, UK
- ⁴⁹Clinical Epidemiology, National Autonomous University of Mexico, Mexico City, Mexico
- ⁵⁰Department of Public Health, Pontifical Catholic University of Chile, Santiago, Chile
- ⁵¹Research Line in Environmental Exposures and Health Effects at Population Level, Centro de Desarrollo Urbano Sustentable (CEDEUS) (Advanced Center for Chronic Diseases [ACCDIS]), Santiago, Chile
- ⁵²Department of Health Systems Management, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
- ⁵³Section of Global Health and Rehabilitation, Western Norway University of Applied Sciences, Bergen, Norway
- ⁵⁴Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway
- ⁵⁵Department of Health Metrics Sciences, University of Washington, Seattle, WA, USA
- ⁵⁶Department of Medical Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- ⁵⁷Division of Cardiology, Atlanta Veterans Affairs Medical Center, Decatur, GA, USA
- ⁵⁸Development of Research and Technology Center, Ministry of Health and Medical Education, Tehran, Iran
- ⁵⁹Health Science Center, University of Texas, Houston, TX, USA
- ⁶⁰Forensic Medicine and Toxicology, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Mangalore, India
- ⁶¹Forensic Medicine and Toxicology, Kasturba Medical College Mangalore, Mangalore, Dakshina Kannada District, Karnataka State, India
- ⁶²Department of Biological Sciences, University of Medical Sciences, Ondo, Ondo, Nigeria
- ⁶³Biomedical Informatics and Medical Statistics Department, Alexandria University, Alexandria, Egypt
- ⁶⁴Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates
- ⁶⁵Egypt Center for Research and Regenerative Medicine (ECRRM), Cairo, Egypt
- ⁶⁶Department of Endemic Medicine and Hepatogastroenterology, Cairo University, Cairo, Egypt
- ⁶⁷Department of Virology, Pasteur Institute of Morocco, Casablanca, Morocco
- ⁶⁸Internal Medicine Department, Hamad Medical Corporation, Doha, Qatar
- ⁶⁹School of Pharmacy, The Chinese University of Hong Kong, Hong Kong, China
- ⁷⁰Department of Pharmacy, Wollega University, Nekemte, Ethiopia
- ⁷¹Institute of Public Health, Charité Medical University Berlin, Berlin, Germany
- ⁷²Department of Radiology, King Edward Memorial Hospital, Mumbai, India
- ⁷³Institute for Physical Activity and Nutrition, Deakin University, Melbourne, VIC, Australia
- ⁷⁴Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- ⁷⁵E-Learning Center, Mashhad University of Medical Sciences, Mashhad, Iran
- ⁷⁶Department of Hepatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
- ⁷⁷Department of Health Systems and Policy Research, Indian Institute of Public Health, Gandhinagar, India
- ⁷⁸Department of Genetics, Sana Institute of Higher Education, Sari, Iran
- ⁷⁹Faculty of Medicine Health and Human Sciences, Macquarie University, Sydney, NSW, Australia
- ⁸⁰School of Medicine, University of Maryland, Baltimore, MD, USA
- ⁸¹Heart, Vascular, Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA

- ⁸²Department of Medicine, Aga Khan University, Karachi, Pakistan
- ⁸³Medical Research Unit, Universitas Syiah Kuala (Syiah Kuala University), Banda Aceh, Indonesia
- ⁸⁴Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran
- ⁸⁵Biology Department, Utica University, Utica, NY, USA
- ⁸⁶Department of Plastic Surgery, University of Texas, Houston, TX, USA
- ⁸⁷National Data Management Center for Health (NDMC), Ethiopian Public Health Institute, Addis Ababa, Ethiopia
- ⁸⁸Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA
- ⁸⁹Division for Health Service Promotion, University of Tokyo, Tokyo, Japan
- ⁹⁰Non-communicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran
- ⁹¹National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- ⁹²Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
- ⁹³School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
- ⁹⁴Burn Research Center, Shahid Motahari Hospital, Tehran, Iran
- ⁹⁵Department of Health Services Administration, China Medical University, Taichung, Taiwan
- ⁹⁶Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China
- ⁹⁷Czech National Centre for Evidence-Based Healthcare and Knowledge Translation, Masaryk University, Brno, Czech Republic
- ⁹⁸Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
- ⁹⁹Department of Health Promotion and Education, University of Ibadan, Ibadan, Nigeria
- ¹⁰⁰Department of Community Medicine, University of Ibadan, Ibadan, Nigeria
- ¹⁰¹Department of Community Medicine, University College Hospital, Ibadan, Ibadan, Nigeria
- ¹⁰²Department of Clinical Pharmacy, MAHSA University, Bandar Saujana Putra, Malaysia
- ¹⁰³School of Health Systems and Public Health, University of Pretoria, Pretoria, South Africa
- ¹⁰⁴Department of Orthodontics & Dentofacial Orthopedics, Dr. D. Y. Patil University, Pune, India
- ¹⁰⁵Functional Neurosurgery Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- ¹⁰⁶Division of Pulmonary Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland
- ¹⁰⁷Postgraduate Institute of Medicine, University of Colombo, Colombo, Sri Lanka
- ¹⁰⁸Department of Surgery, National Hospital, Colombo, Sri Lanka
- ¹⁰⁹Department of Biochemistry, Government Medical College, Mysuru, India
- ¹¹⁰Department of Internal Medicine, GCS Medical College, Hospital & Research Centre, Ahmedabad, India
- ¹¹¹Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland
- ¹¹²Department of Ophthalmology, Heidelberg University, Mannheim, Germany
- ¹¹³Department of Economics, National Open University, Benin City, Nigeria
- ¹¹⁴Department of Family Medicine and Public Health, University of Opole, Opole, Poland
- ¹¹⁵Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran
- ¹¹⁶Department of Oral and Maxillofacial Pathology, Krishna institute of Medical Sciences Deemed to be University, Karad, India
- ¹¹⁷Department of Biomedical sciences, Arba Minch University, Arba Minch, Ethiopia

- ¹¹⁸The Hansjörg Wyss Department of Plastic and Reconstructive Surgery, Nab'a Al-Hayat Foundation for Medical Sciences and Health Care, New York, NY, USA
- ¹¹⁹Cleft Lip and Palate Surgery Unit, Global Smile Foundation, Norwood, MA, USA
- ¹²⁰Department of Endocrinology, Diabetes and Metabolism, Christian Medical College and Hospital (CMC), Vellore, Tamil Nadu, India
- ¹²¹Implementation Science Lab, Baker Heart and Diabetes Institute, Melbourne, India
- ¹²²School of Health Professions and Human Services, Hofstra University, Hempstead, NY, USA
- ¹²³Surgery Research Unit, University of Oulu, Oulu, Finland
- ¹²⁴Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden
- ¹²⁵Students' Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran
- ¹²⁶Family Medicine Department, United Arab Emirates University, Al Ain, United Arab Emirates
- ¹²⁷Primary Care Department, NHS North West London, London, UK
- ¹²⁸Department of Genomics and Digital Health, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Seoul, South Korea
- ¹²⁹Public Health Center, Ministry of Health and Welfare, Wando, South Korea
- ¹³⁰Social Determinants of Health Research Center, Saveh University of Medical Sciences, Saveh, Iran
- ¹³¹Department of Nephrology, Pushpagiri Institute of Medical Sciences and Research Centre, Thiruvalla, India
- ¹³²Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
- ¹³³Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran
- ¹³⁴Pattern Recognition and Machine Learning Lab, Gachon University, Seongnam, South Korea
- ¹³⁵Department of Medicine, University of Science Malaysia, Kota Bharu, Malaysia
- ¹³⁶School of Medical Sciences, University of Science Malaysia, Kota Bharu, Malaysia
- ¹³⁷Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia
- ¹³⁸Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, N.T., China
- ¹³⁹Department of Internal Medicine, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, USA
- ¹⁴⁰Institute of Nutritional Sciences, Friedrich Schiller University Jena, Jena, Germany
- ¹⁴¹Competence Cluster for Nutrition and Cardiovascular Health (nutriCARD), Jena, Germany
- ¹⁴²Department of Anatomy, Gonabad University of Medical Sciences, gonabad, Iran
- ¹⁴³Shiraz University of Medical Sciences, Shiraz, Iran
- ¹⁴⁴Department of Nutrition and Dietetics, University of Concepcion, Concepción, Chile
- ¹⁴⁵Centre for Healthy Living, University of Concepción, Concepción, Chile
- ¹⁴⁶International Dx Department, BGI Genomics, Copenhagen, Denmark
- ¹⁴⁷Breast Surgery Unit, Helsinki University Hospital, Helsinki, Finland
- ¹⁴⁸University of Helsinki, Helsinki, Finland
- ¹⁴⁹University Centre Varazdin, University North, Varazdin, Croatia
- ¹⁵⁰Internal Medicine Programme, Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan
- ¹⁵¹Department of Atherosclerosis and Coronary Heart Disease, National Center of Cardiology and Internal Disease, Bishkek, Kyrgyzstan
- ¹⁵²National Data Management Center for Health, Ethiopian Public Health Institute, Addis Ababa, Ethiopia
- ¹⁵³Department of Basic Medical Sciences, University of Sharjah, Sharjah, United Arab Emirates

- ¹⁵⁴Clinical Epidemiology Research Unit, Mexican Institute of Social Security, Villa de Alvarez, Mexico
- ¹⁵⁵Postgraduate in Medical Sciences, Universidad de Colima, Colima, Mexico
- ¹⁵⁶Laboratory of Public Health Indicators Analysis and Health Digitalization, Moscow Institute of Physics and Technology, Dolgoprudny, Russia
- ¹⁵⁷Experimental Surgery and Oncology Laboratory, Kursk State Medical University, Kursk, Russia
- ¹⁵⁸Mysore Medical College and Research Institute, Government Medical College, Mysore, India
- ¹⁵⁹Department of Dental Public Health, King Abdulaziz University, Jeddah, Saudi Arabia
- ¹⁶⁰Department of Health Policy and Oral Epidemiology, Harvard University, Boston, MA, USA
- ¹⁶¹International Islamic University Islamabad, Islamabad, Pakistan
- ¹⁶²Unit of Microbiology and Public Health, Institute of Medical Sciences, Las Tablas, Panama
- ¹⁶³Department of Public Health, Ministry of Health, Herrera, Panama
- ¹⁶⁴Department of Applied Economics and Quantitative Analysis, University of Bucharest, Bucharest, Romania
- ¹⁶⁵Department of Preventive Medicine, Kyung Hee University, Dongdaemun-gu, South Korea
- ¹⁶⁶Department of General Internal Medicine, Baylor College of Medicine, Houston, FL, USA
- ¹⁶⁷Department of Medicine, Salvador Zubiran National Institute of Medical Sciences and Nutrition, Tlalpan, Mexico
- ¹⁶⁸Department of Biostatistics, University of Washington, Seattle, WA, USA
- ¹⁶⁹Department of Forensic Medicine and Toxicology, Kasturba Medical College, Mangalore, India
- ¹⁷⁰Yonsei University College of Medicine, Yonsei University, Seodaemun-gu, South Korea
- ¹⁷¹Department of Internal Medicine, Ochsner Medical Center, New Orleans, LA, USA
- ¹⁷²Department of General Surgery, University of Texas, Seattle, WA, USA
- ¹⁷³Department of Internal Medicine, Advent Health, Palm coast, FL, USA
- ¹⁷⁴Department of Hospital Medicine, Sound Physicians, PALM COAST, USA
- ¹⁷⁵Department of Medicine, State University of New York, Syracuse, NY, USA
- ¹⁷⁶Department of Biology, University of Bahrain, Sakir, Bahrain
- ¹⁷⁷Medical College, Tairunnessa Memorial Medical College and Hospital, Gazipur, Bangladesh
- ¹⁷⁸School of Public Health, University of Adelaide, Adelaide, SA, Australia
- ¹⁷⁹Department of Biochemistry, Jagadguru Sri Shivarathreeswara University, Mysuru, India
- ¹⁸⁰Department of Cardiology, Emory University, Atlanta, GA, USA
- ¹⁸¹Department of Nephrology, Manipal Academy of Higher Education, Manipal, India
- ¹⁸²Department of Cardiology, Tehran University of Medical Sciences, Tehran, Iran
- ¹⁸³Department of Epidemiology, Non-Communicable Diseases Research Center (NCDRC), Tehran, Iran
- ¹⁸⁴Department of Pharmacology and Toxicology, University of Antioquia, Medellin, Colombia
- ¹⁸⁵Department of Clinical Research, Federal University of Uberlândia, Uberlândia, Brazil
- ¹⁸⁶Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
- ¹⁸⁷Department of Gastroenterology, Tehran University of Medical Sciences, Terhan, Iran
- ¹⁸⁸School of Health Sciences, Foundation University, Islamabad, Pakistan
- ¹⁸⁹International Center of Medical Sciences Research (ICMSR), Islamabad, Pakistan
- ¹⁹⁰Faculty of Medicine, Bioscience and Nursing, MAHSA University, Selangor, Malaysia
- ¹⁹¹Interdisciplinary Research Centre in Biomedical Materials (IRCBM), COMSATS Institute of Information Technology, Lahore, Pakistan

- ¹⁹² Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
- ¹⁹³ Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
- ¹⁹⁴ Department of Community and Family Medicine, All India Institute of Medical Sciences, Bathinda, India
- ¹⁹⁵ Department of Medicine, Tehran University of Medical Sciences, Tehran, Iran
- ¹⁹⁶ Department of Entomology, Ain Shams University, Cairo, Egypt
- ¹⁹⁷ Medical Ain Shams Research Institute, Ain Shams University, Cairo, Egypt
- ¹⁹⁸ Department of Pediatrics, University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH, USA
- ¹⁹⁹ Department of Pediatrics, Case Western Reserve University, Cleveland, OH, USA
- ²⁰⁰ Department of Urban Planning & Design, University of Hong Kong, Hong Kong, China
- ²⁰¹ Department of Medicine, Shifa College of Medicine, Shifa Tameer-e-millat University, Islamabad, Pakistan
- ²⁰² National Heart, Lung, and Blood Institute, National Institute of Health, Rockville, MD, USA
- ²⁰³ Department of Infectious Diseases and Microbiology, Rajiv Gandhi University of Health Sciences, Bangalore, India
- ²⁰⁴ HepatoPancreatoBiliary Surgery and Liver Transplant Unit, HealthCare Global Limited Cancer Care Hospital, Bangalore, India
- ²⁰⁵ Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
- ²⁰⁶ Department of Basic Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
- ²⁰⁷ Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran
- ²⁰⁸ Department of International Studies, Non-Communicable Diseases Research Center (NCDRC), Tehran, Iran
- ²⁰⁹ Department of Medical-Surgical Nursing, Mazandaran University of Medical Sciences, Sari, Iran
- ²¹⁰ Department of Nursing and Health Sciences, Flinders University, Adelaide, SA, Australia
- ²¹¹ School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
- ²¹² Department of Medicine Service, US Department of Veterans Affairs (VA), Birmingham, AL, USA
- ²¹³ Department of Radiodiagnosis, All India Institute of Medical Sciences, Bathinda, India
- ²¹⁴ Maternal and Child Health Division, International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh
- ²¹⁵ Department of Infectious Diseases and Epidemiology, Pirogov Russian National Research Medical University, Moscow, Russia
- ²¹⁶ Department of Hygiene and Public Health, Kanazawa University, Kanazawa, Japan
- ²¹⁷ Trauma and Injury Research Center, Iran University of Medical Sciences, Tehran, Iran
- ²¹⁸ Medical Ethics and Law Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- ²¹⁹ Department of Surgery, National University of Singapore, Singapore, Singapore
- ²²⁰ Rheumatology and Immunology Unit, Mansoura University, Mansoura, Egypt
- ²²¹ Department of Gastroenterology, PSG Institute of Medical Sciences and Research, Coimbatore, India
- ²²² Department of Pharmacy, Komar University of Science and Technology, Sulaymaniyah, Iraq
- ²²³ Urmia University of Medical Sciences, Urmia, Iran
- ²²⁴ UKK Institute, Tampere, Finland
- ²²⁵ Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- ²²⁶ Department of Medicine, Vanderbilt University, Nashville, TN, USA

²²⁷Department of Gastroenterology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China

²²⁸Department of community Medicine, Rajarata University of Sri Lanka, Anuradhapura, Sri Lanka

²²⁹Department of Endocrinology, University of Science and Technology of China, Hefei, China

²³⁰Department of Medicine, University of Rochester, Rochester, NY, USA

²³¹Department of Epidemiology and Biostatistics, Wuhan University, Wuhan, China

²³²Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina, Columbia, SC, USA

²³³Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

²³⁴School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

²³⁵School of Medicine, Wuhan University, Wuhan, China

²³⁶Department of Family Medicine, University of Washington, Seattle, WA, USA.

[AU: Affiliations for all authors in the byline have been included here. Please check and confirm that they are ok.]

Authors' contributions

JVL conceived the idea for this study and prepared a proposal to IHME with HEM. Data collection was led by HH and MAD.

Providing data or critical feedback on data sources

Manik Aggarwal, Ali Ahmadi, Fares Alahdab, Motasem Alkhayyat, Sami Almustanyir, Hubert Amu, Tahira Ashraf, Bantalem Tilaye Tilaye Atinafu, Sara Bagherieh, Mainak Bardhan, Diana Fernanda Bejarano Ramirez, Ajay Nagesh Bhat, Vijay Kumar Chattu, Daniela Contreras, Sandra Cortés, Omar B Da'ar, Bardia Danaei, Rupak Desai, M Ashworth Dirac, Haneil Larson Dsouza, Temitope Cyrus Ekundayo, Iman El Sayed, Noha Mousaad Elemam, Sayeh Ezzikouri, Amr Farwati, Farshad Farzadfar, Ginenus Fekadu, Tushar Garg, Mahaveer Golechha, Pouya Goleij, Vivek Kumar Gupta, Adel Hajj Ali, Saeed S Hamid, Harapan Harapan, Simon I Hay, Reza Homayounfar, Salman Hussain, Segun Emmanuel Ibitoye, Nahlah Elkudssiah Ismail, Linda Merin J, Shubha Jayaram, Bijay Mukesh Jeswani, Jost B Jonas, Abel Joseph, Charity Ehimwenma Joshua, Jacek Jerzy Jozwiak, Vidya Kadashetti, Tesfaye K Kanko, Rami S Kantar, Nitin Kapoor, Moien AB Khan, Sang-wong Lee, Yeong Yeh Lee, Lee-Ling Lim, Stephen S Lim, Stefan Lorkowski, Erkin M Mirrakhimov, Awoke Misganaw, Ali H Mokdad, Jibrán Sualeh Muhammad, Efrén Murillo-Zamora, Christopher J L Murray, Sreenivas Narasimha Swamy, Zuhair S Natto, Robina Khan Niazi, Bogdan Oancea, In-Hwan Oh, Jagadish Rao Padubidri, Seoyeon Park, Harsh K Patel, Venkata Suresh Patthipati, Simone Perna, Vivek Podder, Sina Rashedi, Jefferson Antonio Buendia Rodriguez, Leonardo Roeber, Umar Saeed, Abdallah M Samy, Danish Iltaf Satti, Allen Seylani, Pritik A Shah, Ali Shamekh, Parnian Shobeiri, Jasvinder A Singh, Anna Aleksandrovna Skryabina, Ker-Kan Tan, Nikhil Kenny Thomas, Tommi Juhani Vasankari, Song Wang, Suowen Xu, Chuanhua Yu, and Zhi-Jiang Zhang

Developing methods or computational machinery

Ali Ahmadi, Hubert Amu, Akshaya Srikanth Bhagavathula, Daniela Contreras, M Ashworth Dirac, Adel Hajj Ali, Simon I Hay, Bijay Mukesh Jeswani, Sang-wong Lee, Ali H Mokdad, Christopher J L Murray, Seoyeon Park, Umar Saeed, Abdallah M Samy, and Theo Vos.

Providing critical feedback on methods or results

Amirali Aali, Mohsen Abbasi-Kangevari, Eman Abu-Gharbieh, Manik Aggarwal, Bright Opoku Ahinkorah, Ali Ahmadi, Fares Alahdab, Sami Almustanyir, Hubert Amu, Amir Anoushiravani, Sina Azadnajafabad, Sara Bagherieh, Mainak Bardhan, Diana Fernanda Bejarano Ramirez, Akshaya Srikanth Bhagavathula, Ajay Nagesh Bhat, Mariah Malak Bilalaga, Antonio Biondi, Saeid Bitaraf, Srinivasa Rao Bolla, Daniela Calina, Vijay Kumar Chattu, Sandra Cortés, Omar B Da'ar, Bardia Danaei, Rupak Desai, M Ashworth Dirac, Deepa Dongarwar, Haneil Larson Dsouza, Iman El Sayed, Noha Mousaad Elemam, Mohamed A Elmonem, Aisha Elsharkawy, Sayeh Ezzikouri, Amr Farwati, Florian Fischer, Tushar Garg, Elena S George, Seyyed-Hadi Ghamari, Mohammad Ghasemi Nour, Vivek Kumar Gupta, Parham Habibzadeh, Adel Hajj Ali, Saeed S Hamid, Harapan Harapan, Sanam Hariri, Abbas M Hassan, Simon I Hay, Yuta Hiraike, Reza Homayounfar, Mohammad-Salar Hosseini, Sedighe Hosseini Shabanan, Vivian Chia-rong Hsieh, Junjie Huang, Salman Hussain, Segun Emmanuel Ibitoye, Olayinka Stephen Ilesanmi, Nahlah Elkudssiah Ismail, Chidozie C D Iwu, Linda Merin J, Shubha Jayaram, Bijay Mukesh Jeswani, Jost B Jonas, Abel Joseph, Jacek Jerzy Jozwiak, Ali Kabir, Ali Kabir, Vidya Kadashetti, Tesfaye K Kanko, Rami S Kantar, Nitin Kapoor, Joonas H Kauppila, Moien AB Khan, Min Seo Kim, Carlo La Vecchia, Bagher Larijani, Yeong Yeh Lee, Lee-Ling Lim, Chun-Han Lo, Stefan Lorkowski, Jamal Majidpoor, Mohammad-Reza Malekpour, Yasaman Mansoori, Miquel Martorell, Alexios-Fotios A Mentis, Tuomo J Meretoja, Tomislav Mestrovic, Awoke Misganaw, Abdollah Mohammadian-Hafshejani, Ali H Mokdad, Jibrán Sualeh Muhammad, Efrén Murillo-Zamora, Christopher J L Murray, Mukhammad David Naimzada, Sreenivas Narasimha Swamy, Hasan Nassereldine, Zuhair S Natto, Robina Khan Niazi, Virginia Nuñez-Samudio, Bogdan Oancea, Antonio Olivas-Martinez, Jagadish Rao Padubidri, Seoyeon Park, Harsh K Patel, Venkata Suresh Patthipati, Gayatri Pemmasani, Simone Perna, Vivek Podder, Akila Prashant, Pradhum Ram, Indu Ramachandra Rao, Jefferson Antonio Buendia Rodriguez, Leonardo Roeber, Gholamreza Roshandel, Umar Saeed, Amirhossein Sahebkar, Soumya Swaroop Sahoo, Abdallah M Samy, Chinmoy Sarkar, Danish Iltaf Satti, Allen Seylani, Elaheh Shaker, Parnian Shobeiri, Seyed Afshin Shorofi, Jasvinder A Singh, Paramdeep Singh, Anna Aleksandrovna Skryabina, Joan B Soriano, Majid Taheri, Ker-Kan Tan, Samar Tharwat, Bereket M Tigabu, Marco Vacante, Rohollah Valizadeh, Tommi Juhani Vasankari, Cong Wang, Song Wang, Nuwan Darshana Wickramasinghe, Mazyar Zahir, and Shira Zelber-Sagi.

All authors had full access to all of the data and reviewed and verified the results, and the first draft of the manuscript was prepared by HEM and JVL. All authors reviewed subsequent drafts, approved the final version, and accept responsibility with regard to submitting the manuscript for publication.

[AU: Contributions for all authors have been included here. Please check and confirm that everything is ok.]

Corresponding author

Jeffrey V Lazarus

Barcelona Institute for Global Health (ISGlobal)

Calle del Rosellón 171, ENT-2, ES-08036 Barcelona, Spain

Jeffrey.Lazarus@ISGlobal.org

Tel: +34 608 703 573

Financial support and sponsorship

This work was supported by the EASL International Liver Foundation, which acknowledges funding from Intercept Pharmaceuticals, as well as Bristol Myers Squibb and Merck Sharp & Dohme. S Cortés reports support for the present manuscript from Fondo de Financiamiento de Centros de Investigacion en Areas Prioritarias (FONDAP) (grant number 15130011), outside the submitted work. X Dai reports support for the present manuscript from IHME/UW as a salaried employee. M A Dirac reports support for the present manuscript from the European Association for the Study of the Liver, outside the submitted work. T C Ekundayo reports grants or contracts from The African-German Network of Excellence in Science (AGNES), the Federal Ministry of Education and Research (BMBF), and the Alexander von Humboldt Foundation (AvH) for financial support; all outside the submitted work. V K Gupta reports grants or contracts from the National Health and Medical Research Council (NHMRC), Australia, outside the submitted work. V C Hsieh reports support for the present manuscript from the National Science and Technology Council, Taiwan for Grant # MOST 107-2314-B-039-065-MY3; reports grants or contracts from the National Science and Technology Council, Taiwan for Grant # MOST 107-2314-B-039-065-MY3; all outside the submitted work. A Joseph reports support for the present manuscript from the Bill and Melinda Gates Foundation; reports grants or contracts from the American College of Gastroenterology for a Clinical Research Award; support for attending meetings and/or travel from American College of Gastroenterology Annual Meeting 2022; all outside the submitted work. Y Y Lee reports leadership or fiduciary roles in board, society, committee or advocacy groups, paid or unpaid with Malaysian Society of Gastroenterology and Hepatology as President; all outside the submitted work.

Conflicts of interest

Jeffrey V Lazarus consults for, advises and received grants from AbbVie, Gilead, and Roche. He consults for and advises Novovax. He consults for Novo Nordisk. He received grants from MSD.

Jörn M Schattenberg consults for, is on the speakers' bureau for and received grants from Boehringer Ingelheim. He consults for and is on the speakers' bureau for Novo Nordisk and Madrigal Pharmaceuticals. He consults for and received grants from Gilead Sciences. He consults for Apollo Endosurgery, Albireo Pharma Inc, Bayer, GSK, Intercept Pharmaceuticals, Ipsen, Inventiva Pharma, MSD, Northsea Therapeutics, Novartis, Pfizer, Roche, Sanofi, and Siemens Healthineers. He is on the speakers' bureau for Echosens and MedPublico GmbH. He received grants from Siemens Healthcare GmbH. . N E Ismail

reports leadership or fiduciary roles in board, society, committee or advocacy groups, paid or unpaid with Malaysian Academy of Pharmacy as council member, outside the submitted work. J J Jozwiak reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from NOVART and ADAMED, outside the submitted work. Y Y Lee reports grants or contracts from NAFLD-related Clinical Trial Investigator for Novo Nordisk and Boehringer Ingelheim. L Lim reports grants or contracts from Boehringer Ingelheim, AstraZeneca, and Abbott Nutrition; all outside the submitted work. S Lorkowski reports grants or contracts from Akcea. All other authors have no conflicts of interest to report.

[Conflicts for all named authors have been placed here. Please check and confirm if this is ok.]

Keywords

NAFLD; NASH; public health; health index; health policy

Abbreviations

NASH, non-alcoholic steatohepatitis

NCD, non-communicable disease

T2DM, type 2 diabetes mellitus

NAFLD, non-alcoholic fatty liver disease

SDG, Sustainable Development Goal

UHC, universal health coverage

UGS, urban green space score

GBD, Global Burden of Diseases, Risk Factors, and Injuries Study

UI, uncertainty interval

HDI, Human Development Index

ACCEPTED

Graphic abstract

GA1

Abstract

Background & Aims: Fatty liver disease is highly prevalent, resulting in overarching wellbeing and economic costs. Addressing it requires comprehensive and coordinated multisectoral action. We developed a fatty liver disease-Sustainable Development Goal (SDG) country score to provide insights into country-level preparedness to address fatty liver disease through a whole-of-society lens.

Approach & Results: We developed two fatty liver disease-SDG score sets. The first included six indicators (child wasting, child overweight, non-communicable disease [NCD] mortality, universal health coverage service coverage index, health worker density, and education attainment), covering 195 countries between 1990-2017. The second included the aforementioned indicators plus an urban green space (UGS) indicator, covering 60 countries for which 2017 data were available. To develop the fatty liver disease-SDG score, indicators were categorised as “positive” or “negative” and scaled from 0–100. Higher scores indicate better preparedness levels. Fatty liver disease-SDG scores varied between countries (n=195), from 14.6 (95% UI 8.9–19.4) in Niger to 93.5 (91.6–95.3) in Japan; 18 countries scored >85. Regionally, the high-income super-region had the highest score at 88.8 (87.3–90.1) in 2017, while south Asia had the lowest score at 44.1 (42.4–45.8). Between 1990-2017, the fatty liver disease-SDG score increased in all super-regions, with the greatest increase in south Asia, but decreased in eight countries.

Conclusions: The fatty liver disease-SDG score provides a strategic advocacy tool at the national and global levels for the liver health field and NCD advocates, highlighting the multi-sectoral collaborations needed to address fatty liver disease, and NCDs overall.

Introduction

Fatty liver disease refers to a range of conditions in which excess fat builds up in the liver, and is largely unknown among the general population,¹ health policy makers, and the global public health community.² This potentially serious condition is estimated to affect about one in three adults globally³, and is increasingly problematic in children and adolescents.⁴⁻⁶

Disease severity is measured through the degree of fibrosis; however, population-based estimates of advanced fibrosis associated with fatty liver disease are limited. Data from Germany have shown this to be around 1%,⁷ while a Korean study estimated this at 2.6%.⁸ A review of studies in patients at risk of clinically significant liver disease in a general population setting found that the prevalence of advanced liver fibrosis ranged between 0.9% and 2.0%, and cirrhosis between 0.1% and 1.7%.⁹ Fatty liver disease, and particularly the more aggressive condition, non-alcoholic steatohepatitis (NASH), have a substantial impact on individual health,¹⁰ burdening health systems and causing substantial economic encumbrance and increasing wellbeing costs.¹¹

Beyond being a leading cause of cirrhosis¹² and liver cancer,^{13,14} fatty liver disease shares a close bidirectional relationship with other highly prevalent non-communicable diseases (NCDs), most notably cardiovascular disease, type 2 diabetes mellitus (T2DM), obesity, and non-hepatic cancers.¹⁵⁻¹⁷ In the majority of patients, fatty liver disease emerges in the context of metabolic syndrome.¹⁷ Although fatty liver disease is strongly associated with obesity,¹⁸ it is still prevalent in non-obese individuals, especially those of Asian descent.¹⁹ As a consequence of the lack of overall awareness about the condition, fatty liver disease continues to go largely undiagnosed among the general population,²⁰ even among some high-risk populations such as people diagnosed with T2DM.²¹ Furthermore, fatty liver disease is asymptomatic until the occurrence of severe complications, making it difficult to identify the disease²⁰ and implement treatment and care interventions, such as lifestyle modification. Much like the other major public health challenges of the 21st century, fatty liver disease requires systems thinking alongside multidisciplinary and multisectoral responses²² that address the immediate and underlying determinants of the disease. Yet, despite the scale of the challenge posed by fatty liver disease, health system and public health responses have generally been weak and fragmented.^{2,23,24} A 2020 study captured data on non-alcoholic fatty liver disease (NAFLD)-related policies and guidelines in 102 countries, creating a NAFLD preparedness index which characterised the health system and public health responses in the participating countries. The study found that no country had a written strategy to address the disease and, in most countries, NAFLD was absent within strategies and guidelines for related

conditions, including obesity and diabetes.² To fill the dearth of strategic guidance, a consortium of 218 experts from 91 countries recently developed NAFLD consensus statements and recommendations to advance public health and policy agendas.²⁵ While health systems sit at the centre of efforts to address the burden of fatty liver disease, tackling this public health challenge will require action well beyond the health sector. To help the public health community and those across other sectors to conceptualise the design of whole-of-society responses to fatty liver disease, we previously published a Sustainable Development Goal (SDG)-NAFLD framework.²⁶ The SDGs serve as the mainstay of the 2030 Agenda for Sustainable Development, with clear priorities, from reducing social and economic inequalities to improving nutrition, health, and education, and were adopted by all United Nations member states in 2015. Using the SDGs as a multisectoral framework for action,²⁷ a multidisciplinary group followed a standard Delphi process to identify the targets and indicators most relevant to NAFLD, with the final framework including seven indicators. The framework is intended as a strategic advocacy tool to build the case for closer collaboration within and between sectors to address fatty liver disease and other NCDs. Similar work has previously been undertaken to develop a framework to inform policy approaches on sustainable development and urban health²⁸ and to highlight the importance of addressing obesity for achieving the SDG agenda.²⁹ Here, we present the development of the first fatty liver disease-SDG score, covering 195 countries from 1990 to 2017. The fatty liver disease-SDG score builds on the earlier framework to providing a multisectoral lens through which to view country-level preparedness to address the challenge of fatty liver disease, and to guide future health and development sector collaboration and action on this issue.

Methods

Fatty liver disease-SDG framework

The fatty liver disease-SDG framework underpinning the fatty liver disease-SDG score was developed through a Delphi process. First, a core team of researchers reviewed the SDG targets and indicators,³⁰ identifying those directly or indirectly associated with fatty liver disease. Subsequently, a multidisciplinary group of experts (n=15) were invited to select which of the shortlisted targets and indicators to include in the fatty liver disease-SDG framework. Targets and indicators with 75% or greater agreement were included in the final fatty liver disease-SDG framework, with this framework comprising 16 targets and seven indicators (Figure 1). The detailed methodology has been previously published.²⁶

Development of the fatty liver disease-SDG score

The indicators included in fatty liver disease-SDG score are shown in Table 1. We developed two sets of fatty liver disease-SDG scores. The first set was developed using six indicators (child wasting, child overweight, NCD mortality, a universal health coverage [UHC] service coverage index, health worker density, and education attainment) and excluded the urban green space score (UGS) since it was not available for all countries. It covers 195 countries and territories between 1990 and 2017. The second set was constructed using all seven indicators and includes only the 60 countries for which the UGS data were available in 2017. The estimates for child wasting, child overweight, NCD mortality, the UHC service coverage index, health worker density, and education attainment came from the Global Burden of Diseases, Risk Factors, and Injuries Study (GBD).³¹⁻³³ Details of the input data and modelling procedures for estimating these indicators have been published previously.³⁴ The data for UGS were extracted from a published study conducted by Kwon et al.³⁵ UGS is a globally comparable metric computed using Sentinel-2 satellite imagery data.³⁶

We took an analytical approach similar to the GBD's health-related SDG index to develop the fatty liver disease-SDG score. First, indicators were grouped into either a "positive" or "negative" category. The "positive" category consisted of indicators where higher estimates were associated with better health outcomes (e.g., UHC service coverage index). The "negative" category consisted of indicators where lower estimates were associated with better health outcomes (e.g., child wasting).

Then, all indicators were scaled from 0–100, with 0 denoting the worst observed performance and 100 reflecting the best performance, to make them comparable. To reduce the sensitivity of extreme outliers in a given location-year, we set the lower bound at the 2.5th percentile and the upper bound at the 97.5th percentile of the distribution, for a given indicator. For "positive" indicators, any value below the 2.5th percentile was assigned a value of 0, and any value exceeding the 97.5th percentile was assigned a value of 100. The "negative" indicators were scaled and adjusted for outliers similarly, but with 0 assigned to any value exceeding the 97.5th percentile, and 100 assigned to any value below the 2.5th percentile, over the same study period. A modified scaling approach was applied to two indicators: NCD mortality and health worker density. Specifically, NCD mortality was scaled in log-space. Health worker density was scaled to reflect the density of each health worker cadre (i.e., physicians, nurses, midwives, and pharmacists). The details of the modified scaling approach for health worker density have been previously published.³⁴

The final fatty liver disease-SDG score was calculated in two steps. First, we computed the geometric mean of child wasting and child overweight, two indicators that fall under the same

SDG target.³⁴ Then, we computed the geometric mean of the remaining indicators including the aggregate child wasting and child overweight score. In both steps, we restricted draws of each indicator score to a minimum value of 1 before computing the geometric mean to mitigate issues with values close to 0. To generate the fatty liver disease-SDG score for the seven standard GBD super-regions,³⁷ we aggregated the national-level, unscaled estimates of each indicator for each super-region, using population weights. Then, the national-level 2.5th and 97.5th percentile values for each indicator were applied to scale the indicators for each super-region location, before taking the geometric mean of the indicators, to produce the final fatty liver disease-SDG scores.

Every analytic step was carried out for 1000 draws from the posterior distribution of the previous step, to ensure uncertainty from all inputs, and analyses were propagated through to the final scores. Uncertainty intervals (UIs) were obtained by taking the 2.5th and 97.5th percentiles of the 1000 draw values.

Combining the fatty liver disease-SDG scores with the NAFLD preparedness index

In contrast to our fatty liver disease-SDG score, which aims to measure preparedness to address fatty liver disease from a multisectoral, whole-of-society perspective, the previously described NAFLD preparedness index² reports a country's preparedness to address NAFLD specifically from a health systems and public health policy perspective. After development of the fatty liver disease-SDG scores, we combined them with the NAFLD preparedness index for a more comprehensive assessment of countries' fatty liver disease preparedness. Fatty liver disease-SDG scores for 100 countries included in the NAFLD preparedness index were extracted and then ranked. Two countries/territories included in the NAFLD preparedness index (Aruba and Hong Kong) were not included in the fatty liver disease-SDG index, and hence were excluded. For these 100 countries, we summed the country rankings for the fatty liver disease-SDG score with the rankings of the NAFLD preparedness index.

Comparing the fatty liver disease-SDG scores to the NAFLD preparedness index and the HDI

We separately compared the 2017 estimates of fatty liver disease-SDG scores to the NAFLD preparedness index² and the Human Development Index (HDI).³⁸ The HDI is a composite index of life expectancy, level of education attainment, and gross national income per capita that measures the overall human development of a country. The HDI covers some of the themes also captured in the fatty liver disease-SDG score, namely education; however, it does not incorporate key issues for fatty liver disease such as health service coverage or access to urban green spaces, which are included in the fatty liver disease-SDG score. Two countries/territories (Aruba and Hong Kong) were excluded from this comparison analysis

between fatty liver disease-SDG scores and NAFLD preparedness index, while seven countries/territories (Hong Kong, Liechtenstein, Palau, Saint Kitts and Nevis, San Marino, Eswatini, and Tuvalu) were excluded for the fatty liver disease-SDG score and HDI comparison.

Results

The fatty liver disease-SDG scores for the 195 countries and territories vary substantially, from 14.6 (95% UI 8.92–19.4) in Niger to 93.5 (91.6–95.3) in Japan, with 18 countries scoring >85 on the 0–100 scale (Figure 2A; see Supplementary Table 1 and 2 <http://links.lww.com/HEP/F1000> for country scores from 1990 to 2017). The standard deviation of the fatty liver disease-SDG score across all 195 countries in 2017 is 18.58, and the interquartile range is 26.81. The standard deviation and interquartile range of the fatty liver disease-SDG score by GBD super-region can be found in Supplementary Table 3 <http://links.lww.com/HEP/F1000>.

Regionally, the high-income super-region had the highest score at 88.8 (95% UI 87.3–90.1) in 2017, and south Asia had the lowest score at 44.1 (42.4–45.8). Between 1990 and 2017, the fatty liver disease-SDG score improved in all seven super-regions, with the percentage increase ranging from 13.3% to 181.2% (Figure 3). The greatest improvement was in south Asia, despite its poor performance in absolute terms.

Across the 195 countries and territories, the fatty liver disease-SDG score decreased (worsened) in eight countries during the study period, with the largest decrease in Guam (–27.9% [95% UI –32.8 to –20.2]) (Supplementary Table 4 <http://links.lww.com/HEP/F1000>). On the other hand, the biggest fatty liver disease-SDG score increase (improvement) was observed in Eritrea (1116.1% [531.3–1913.1]), followed by Ethiopia (645.9% [382.6–764.9]) and Laos (628.3% [324.0–1292.3]).

Of the six indicators that were used to develop the fatty liver disease-SDG score, the UHC service coverage index had the lowest average scaled value across all 195 locations. This was consistent when restricted to the countries with the bottom 20% of the fatty liver disease-SDG scores. The second lowest indicator, however, differed in those two groups. When compared across all 195 locations, the indicator with the second lowest scaled value was NCD mortality, whereas when restricted to the bottom 20% the second lowest was education attainment.

For the 60 countries where UGS data were available (Figure 2B, Supplementary Table 5 <http://links.lww.com/HEP/F1000>), the inclusion of the indicators had variable impacts on the fatty liver disease-SDG country scores (Figure 2C). In 21 countries (35%), the inclusion of

UGS improved the score, while in 39 countries (65%), the score worsened with inclusion of this indicator. The average percentage improvement in the score including UGS was 2.62% (95% UI 0.83–3.82), while the average decrease was 9.29% (7.04–11.92) (Figure 2C).

Montenegro had the biggest improvement in score with the inclusion of UGS (8.37%), while Bahrain had the largest decrease (51.4%).

Sweden had the highest overall combined rank when comparing the fatty liver disease-SDG score and NAFLD preparedness index (ranked fourth for the fatty liver disease-SDG score and third on the NAFLD preparedness index), while Central African Republic had the lowest (ranked 96th for the fatty liver disease-SDG score and joint 71st on the NAFLD preparedness index). Sweden, the UK, Belgium, Germany, and Israel ranked in the top 15 on both indices. The largest difference between the fatty liver disease-SDG score and NAFLD preparedness index was seen in India, which ranked 88th on the former and first on the latter (Supplementary Table 6 <http://links.lww.com/HEP/F1000>).

The comparisons of the national fatty liver disease-SDG scores to the NAFLD preparedness index and HDI are shown in Figure 4 (Supplementary Table 7 and 8 <http://links.lww.com/HEP/F1000>). Although many countries across all seven GBD super-regions had near zero NAFLD preparedness index values, countries with higher NAFLD-SDG score were more likely to score higher on the NAFLD preparedness index. A few notable exceptions were found. India and Bulgaria, two countries with sub-optimal fatty liver disease-SDG scores, had one of the highest NAFLD preparedness index values. The correlation was higher, but not 100%, between the fatty liver disease-SDG score and the HDI.

Discussion

There have been increasingly frequent calls to focus on systems thinking and to develop new tools to conceptualise and implement the complex responses needed to address today's major health challenges,²² including the partnerships and collaborations that sit at the centre of systems responses. In this study, we present a novel score for 195 countries and territories (1990 to 2017) which uses the SDG framework as a lens through which to assess countries' preparedness to tackle fatty liver disease. The burden of fatty liver disease is high³ and rapidly increasing,³⁹ and it is already the fastest growing cause of hepatocellular carcinoma in France, the UK, and the USA. The incidence of NAFLD-related hepatocellular carcinoma is projected to increase dramatically by 2030, with increases of 82%, 117%, and 122% from 2016 in China, France, and the USA, respectively.⁴⁰ Fatty liver disease is an archetypical public health issue of the 21st century, requiring action across a wide range of sectors and disciplines. While the focus of this study was fatty liver disease, the findings have broader

relevance to NCDs, especially to closely related conditions such as T2DM, cardiovascular disease, and obesity.

We suggest the fatty liver disease-SDG score for three primary uses. Given the lack of awareness about fatty liver disease and the importance of a multisectoral approach in tackling this public health challenge, the score can help to create awareness among key stakeholder groups, within and beyond the health sector. Secondly, the score can be an advocacy tool for public health professionals, civil society, and patient groups to advocate for greater action across sectors on this neglected public health challenge, at national and global levels. Finally, the score can inform the strategic decision-making within national, regional and global liver and other NCD organisations about the types of cross-sectoral actors they should be engaging and collaborating with. While there is some correlation between the fatty liver disease-SDG score and existing scores, such as the HDI, the new score provides a more granular focus on the key issues impacting fatty liver disease and will support more nuanced discussions at a strategic and policy level. If the score is updated periodically (e.g., every three to five years), advocates can also use it to scrutinise success and challenges over time, including policy changes. The fatty liver disease-SDG score provides a holistic multisectoral lens through which to view efforts to address fatty liver disease, complementing existing efforts, such as the NAFLD preparedness index, which take a focused look at health systems and public health responses within countries. Furthermore, the data employed to calculate the score are regularly and consistently collected for 195 countries and territories, while the preparedness index had data from only 102 countries.²

As expected, high-income countries generally had higher fatty liver disease-SDG scores than low-income and lower-middle-income countries. There were some notable exceptions, including Uruguay, Brunei, and Qatar, none of which scored in the top quartile of countries. This highlights that advanced economic development is not a guarantee of a higher fatty liver disease-SDG score, emphasising the importance of focused policy interventions aimed at addressing the underlying and direct drivers of public health. These may, for example, target inadequate nutrition and sedentary lifestyles at the population level.⁴¹ Although fatty liver disease is a pressing public health problem, no country is yet fully prepared to address it.²⁵ Geographically, sub-Saharan Africa and south Asia were the GDB super-regions with the lowest scores; however, some countries in these regions performed well overall, such as Cabo Verde and Botswana, which both ranked higher than other more economically advanced countries, highlighting that low- and middle-income countries can take strides in preparing to address conditions such as fatty liver disease.

For the 60 countries where UGS data were available, the inclusion of this indicator had varying impacts on the overall score, improving it in just over one-third of countries and reducing it in the remainder, in the case of Bahrain by over 50%. While we were unable to include UGS data in the score for all countries, we believe that this indicator captures critical information on the environment in which people live. Importantly, the availability of UGS does not guarantee access and utilisation, two points which are not reflected in our score. The use of green space is impacted by socioeconomic and socio-cultural factors,^{42,43} and efforts to increase the availability of UGS need to be accompanied by other interventions to increase access and use, such as improved security and lighting. This is especially important among those who can benefit the most from using such space, including people at a higher risk of fatty liver disease and other NCDs, considering UGS effects on both physical and mental health.

Whole-of-society and health system responses

We combined the ranking of countries on the fatty liver disease-SDG score with a previously published NAFLD preparedness index.² While the fatty liver disease-SDG score provides a multisectoral perspective which speaks to a country's action on fatty liver disease and NCDs more broadly, the NAFLD preparedness index gives insights into the relevant health system policy, guidelines, and strategies that are in place to address NAFLD. By comparing how well countries performed across both indices, we aimed to provide a holistic view of a country's preparedness to address this public health challenge. Countries that rank highly on both the fatty liver disease-SDG and NAFLD preparedness indices are best prepared to address the challenge of fatty liver disease. The NAFLD preparedness index found substantial variation between countries' readiness to address NAFLD. Notably, even those countries that score relatively highly exhibit deficiencies in key domains, suggesting that structural changes are needed to optimise NAFLD management and ensure that effective public health approaches are in place.⁴² Further detailed analysis at the regional level of countries ranking highly on both indices could provide useful case studies to understand the policy measures that have been implemented and how these could be implemented in other national or subnational contexts.

Informing national responses to fatty liver disease

While national development priorities vary, fatty liver disease – and NCDs more broadly – are important considerations for decisionmakers in all countries. For example, in low-income and lower-middle-income countries, where public health issues have traditionally focused on communicable diseases, NCDs are becoming a major cause of morbidity and mortality,^{44,45}

with important implications for individual health, health systems, and economic development.^{46,47}

Fatty liver disease, to date, is not addressed in global health policy or technical guidance. Improving public health is a central pillar for the SDG agenda⁴⁸ and should be a primary goal in all countries as a means of driving economic and social progress. While health system preparedness, underpinned by achieving UHC and health equity, is crucial, the underlying causes of fatty liver disease and other highly prevalent diseases cannot be addressed in the health sector alone. Our findings re-emphasise the longstanding calls for health in all policies' approach.

Several of the indicators in this novel fatty liver disease-SDG index, namely, education and availability of UGS, fall beyond the direct scope of the public health community, pointing to the need to engage across various sectors, and for the public health community to support and champion the work of other sectors. Successful multisectoral action requires strong governance mechanisms that enable different stakeholders to collaborate around shared goals. Such governance structures are frequently missing or insufficient, especially in low- and middle-income countries, where institutions are commonly weak, and where fragmentation is common.⁴⁹ More detailed analysis is still needed to understand how multisectoral action can best work in practice.

Limitations

This study has several limitations. There is variation in the clinical definition for fatty liver disease, and countries may monitor the disease using different methods. Hence, the full burden and impact of the disease is unknown, precluding the potential to externally validate the fatty liver disease-SDG score using the estimated disease burden of fatty liver disease and NASH in each country. While such a validation would theoretically show if higher-scoring countries have a lower disease burden and vice versa, interpretation of such an analysis is challenging, in part because primary data on fatty liver disease prevalence are scant and heterogeneous. Changes in fatty liver disease epidemiology occur slowly over time; in theory, the fatty liver disease-SDG scores for 1990, 2000, and 2010 will provide useful insights into the disease burden today, yet the myriad of confounding factors and data quality over this time makes such comparisons fraught.

Further, we recognise that our combination of the fatty liver disease-SDG score with the NAFLD preparedness index uses data from different time points, with the former using data from 2017 – the latest available data – and the latter from 2020. However, we suggest that it

is unlikely that the fatty liver disease-SDG score will have changed substantially between these timepoints and find value in the aggregate score.

One SDG indicator (16.1.4; Proportion of population that feel safe walking alone around the area they live after dark) was included in the fatty liver disease-SDG framework²⁶; however, data for this indicator were unavailable to include in the fatty liver disease-SDG score.³⁰ We note that the metric for UGS was developed using data from only 90 cities within the 60 countries included and may thus not be an accurate representation of UGS throughout each country. We also had no information available regarding the quality of UGS scores. For example, there is uncertainty as to whether the UGS practically relates to better walkability and ability to perform outdoor exercise, as green spaces have different factors for usability not captured in a single metric, including safety and environmental health risks.^{50,51}

Conclusions

We present a novel fatty liver disease-SDG score for 195 countries and territories over three decades with the aim of supporting efforts to address the public health challenge of fatty liver disease through a whole-of-society approach. Fatty liver disease remains a high-prevalence, largely unknown, and under-addressed disease, yet one that will have an increasing impact on health, health systems, and economies in the years ahead. The fatty liver disease-SDG score can help support efforts to raise awareness about fatty liver disease, and ultimately assist all levels of the policy-making processes.

Acknowledgments

A Ahmad would like to thank the Deanship of Scientific Research at Shaqra University for supporting this work. V C Hsieh acknowledges support from the National Science and Technology Council, Taiwan (Grant # MOST 107-2314-B-039-065-MY3). M A Dirac acknowledges support from the Global Public Goods Grant from Bill & Melinda Gates Foundation. V K Gupta acknowledges funding support from National Health and Medical Research Council (NHMRC), Australia. S Hussain acknowledges support from Operational Programme Research, Development and Education Project, Postdoc2MUNI (No. CZ.02.2.69/0.0/0.0/18_053/0016952). S Lorkowski acknowledges funding by the German Federal Ministry of Education and Research (nutriCARD, grant agreement number 01EA1808A). V Nuñez-Samudio acknowledges support from Panamá's La Secretaría Nacional de Ciencia, Tecnología e Innovación (Senacyt) as a member of the Sistema Nacional de Investigación (SNI). J R Padubidri acknowledges support from Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal in supporting collaborative research. A M Samy acknowledges the support from Ain Shams University and the Egyptian Fulbright Mission Program.

Assistance with the study: [AU: We recommend that you include a general acknowledgment to non-author contributors here then submit the full list of group members as a supplemental document. Non-author contributors will not be indexed in PubMed.]

The GBD Fatty Liver Disease-SDG Collaborators:

Jeffrey V Lazarus^{1,2,3,4}, Hannah Han⁵, Henry E Mark², Saleh A Alqahtani⁶, Jörn M Schattenberg⁷, Joan B Soriano^{8,9}, Trenton M White¹, Shira Zelber-Sagi^{10,11}, M Ashworth Dirac^{5,12}, Amirali Aali¹³, Mahdieh Abbasalizad-Farhangi¹⁴, Hyder Abbasi¹⁵, Mohsen Abbasi-Kangevari¹⁶, Amir Abdoli¹⁷, Shima Abdollahi¹⁸, Ashkan Abdollahi¹⁹, Semaw Abera²⁰, Melka Aboye²¹, Eman Abu-Gharbieh²², Osama Abu-Shawar²³, Ahmed Abu-Zaid²⁴, Rufus Adedoyin²⁵, Prabhat Adhikari²⁶, Sangeet Adhikari²⁷, Mina Adib²⁸, Kossivi Afanvi²⁹, Mohsen Afarideh³⁰, Manik Aggarwal²³, Mohamad Aghaie Meybodi³¹, Sutapa Agrawal³², Ghelvin Auriele Aguirre³³, Bright Ahinkorah³⁴, Aqeel Ahmad³⁵, Ali Ahmadi³⁶, Elham Ahmadian¹⁴, Hooman Ahmadzadeh¹⁶, Koohyar Ahmadzadeh³⁷, Haroon Ahmed³⁸, Elham Ahmed³⁹, Tomi Akinyemiju⁴⁰, Hanadi Al Hamad⁴¹, Omar Al Omari⁴², Fares Alahdab⁴³, Abdulhadi Alamodi⁴⁴, Cenon Alfonso⁴⁵, Mohammed Sanni Ali⁴⁶, Motasem Alkhayyat²³, Amir Almasi-Hashiani⁴⁷, Rasha Almubark⁴⁸, Abdulaziz Almulhim⁴⁹, Sami Almustanyir²⁴, Mohammed Mansour Alshehri⁵⁰, Saba Alvand¹⁶, Hubert Amu⁵¹, Catalina Liliana Andrei⁵², Susan Anenberg⁵³, Abebayehu Aniley⁵⁴, Amir Anoushiravani¹⁶, Olga Antsygina⁵⁵, Palwasha Anwari⁵⁶, Ephrem Mebrahtu Araya⁵⁷, Mohammad Arjomandzadegan⁴⁷, Dorsa Arman Moghadam⁵⁸, Tahira Ashraf⁵⁹, Elaheh Askari⁶⁰, Bahar Ataeinia⁴², Zerihun Ataro⁶¹, Tesfay Mehari Atey²⁰, Bantalem Tilaye Atinifu⁶², Floriane Ausloos⁶³, Ashish Awasthi⁶⁴, Daniel Ayamga⁶⁵, Yohanes Ayele⁶¹, Meshesha Ayele⁶⁶, Sina Azadnajafabad¹⁶, Mohammadreza Azangou-Khyavy⁶⁷, Abdullah Zoheb Azhar⁶⁸, Amir Azimi³⁷, Nicolae Bacalbasa⁵², Umar Bacha⁶⁹, Nayereh Baghcheghi⁷⁰, Sayna Bagheri¹⁶, Sara Bagherieh⁷¹, Nafiseh Baheiraei⁷², Ahmed Bakhshwin²³, Joseph Banoub⁷³, Mainak Bardhan⁷⁴, Simon Barquera⁷⁵, Ali Bassir⁷⁶, Estifanos Baye⁷⁷, Diana Bejarano Ramirez⁷⁸, Solomon Bekele⁶⁶, Abate Belachew⁷⁹, Sefealem Belay⁸⁰, Yaschilal Belayneh⁷⁷, Abebe Belete⁶², Ashenafi Berchedi⁸¹, Kebede Beyene⁸², Akshaya Bhagavathula⁸³, Neeraj Bhala⁸⁴, Divya Bhandari⁸⁵, Ajay Bhat⁸⁶, Vijayalakshmi Bhojaraja⁸⁷, Belete Biadgo⁸⁸, Ali Bijani⁸⁹, Mariah Malak Bilalaga²², Awraris Bilchut⁶², Bagas Suryo Bintoro⁹⁰, Antonio Biondi⁹¹, Tsegaye Birhan⁸⁸, Bihungum Bista Bista⁹², Saeid Bitaraf⁹³, Srinivasa Rao Bolla⁹⁴, Archith Boloor⁸⁶, Antonio Borzi⁹¹, Antoine Boustany²³, Daniela Calina⁹⁵, Luis Cámara⁹⁶, Ismael Campos-Nonato⁷⁵, Muge Cevik⁹⁷, Joshua Chadwick⁹⁸, Raja Chandra Chakinala⁹⁹, Ana Paula Champs³⁹, Mei Yen Chan¹⁰⁰, Jaidev Chandan¹⁰¹, Vijay Kumar Chattu¹⁰², Nagendra Chaudhary¹⁰³, Huzaiifa Cheema¹⁰⁴, Sungchul Choi¹⁰⁵, Sheng-Chia

Chung¹⁰⁶, Cain Clark¹⁰⁷, Federico Conforto¹⁰⁸, Kathleen Corey⁴², Jorge Correia¹⁰⁹, Sandra Cortés¹¹⁰, Paolo Cortesi¹¹¹, Vera Costa¹¹², Ewerton Cousin¹¹³, Benjamin Cowie¹¹⁴, Omar Da'ar¹¹⁵, Omid Dadras¹¹⁶, Baye Dagne⁸⁸, Sushil Dahal¹¹⁷, Bardia Danaei⁶⁷, Parnaz Daneshpajouhnejad¹¹⁸, Chau Dang¹¹⁹, Anh Dang¹²⁰, William Dangel¹²¹, Ahmad Daryani¹²², Barbora De Courten¹²³, Zeleke Demissie⁷⁷, Gebre Demoz¹²⁴, Rupak Desai¹²⁵, Fikadu Dessalegn¹²⁶, Syed Masudur Rahman Dewan¹²⁷, Arkadeep Dhali¹²⁸, Meghnath Dhimal⁹², Shirin Djalalinia¹²⁹, Thanh Do¹³⁰, Huyen Do¹³¹, Hoa Do¹²⁰, Milad Dodangeh³⁷, Deepa Dongarwar¹³², Majid Dousti¹³³, Haneil Dsouza⁸⁶, Abebe Dukessa²¹, Susanna Dunachie¹³⁴, Bruce Duncan¹³⁵, Hedyeh Ebrahimi¹⁶, Temitope Ekundayo¹³⁶, Iman El Sayed¹³⁷, Sameh Elawady¹³⁸, Noha Elemam²², Mohamed Elmonem¹³⁹, Aisha Elsharkawy¹⁴⁰, Zahra Esfahani¹⁴¹, Arash Etemadi¹⁴², Tahir Eyayu¹⁴³, Sayeh Ezzikouri¹⁴⁴, Hafsa Faisal¹⁴⁵, Shahab Falahi¹⁴⁶, Umar Farooque¹⁴⁷, Sarah Farran¹⁴⁸, Amr Farwati⁴¹, Farshad Farzadfar¹⁶, Syeda Sadia Fatima¹⁴⁹, Nima Fattahi¹⁶, Ginenus Fekadu¹⁵⁰, Desalegn Feyissa⁸¹, Julia Finkelstein¹⁵¹, Florian Fischer¹⁵², Karen Forrest¹⁵³, Anis Fuad⁹⁰, Shilpa Gaidhane¹⁰², Tushar Garg¹⁵⁴, Abadi Gebre²⁰, Lemlem Gebremariam²⁰, Mathewos Gebremichael⁶⁶, Johanna Geleijnse¹⁵⁵, Tadele Gemechu¹²⁶, Belete Gameda⁶², Elena George¹⁵⁶, Urge Gerema²¹, Melaku Getachew⁶¹, Maryam Ghadimi¹⁹, Seyyed-Hadi Ghamari¹⁶, Mohammad Ghasemi Nour¹³, Hamidreza Ghasemirad¹⁵⁷, Ahmad Ghashghae¹⁵⁸, Maryam Gholamalizadeh⁶⁷, Ali Gholami¹⁵⁹, Paramjit Gill¹⁰¹, Justyna Godos⁹¹, Amit Goel¹⁶⁰, Mahaveer Golechha¹⁶¹, Pouya Goleij¹⁶², Golnaz Goodarzi¹⁶, Mekonnen Goyteom⁵⁷, Giuseppe Grosso⁹¹, Vivek Gupta¹⁶³, Joseph Habib¹⁶⁴, Parham Habibzadeh¹³³, Nguyen Hai Nam¹⁹, Teklehaimanot Haile¹²⁴, Gessesew Hailu²⁰, Mehdi Hajjani¹⁶⁵, Adel Hajj Ali²³, Saeed Hamid¹⁴⁹, Soroosh Hamzeh³⁷, Md. Abdul Hannan¹⁶⁶, Harapan Harapan¹⁶⁷, Sanam Hariri¹⁶, Netanja Harlianto¹⁶⁸, Mehdi Harorani⁴⁷, Milad Hasankhani¹⁴, Mohammad Rashidul Hashan¹⁶⁹, Seyedeh Melika Hashemi¹⁴¹, Maryam Hashemian¹⁷⁰, Shoaib Hassan¹⁷¹, Abbas Hassan¹³², Habtemu Hebo¹²⁶, Behnam Heidari¹⁶, Golnaz Heidari³⁹, Yuta Hiraike¹⁷², Minh Hoang¹³¹, Reza Homayounfar¹⁷³, Mohammad-Salar Hosseini¹⁴, Sedighe Hosseini Shabanian¹⁶, Soodabeh Hoveidamanesh¹⁷⁴, Vivian Chia-Rong Hsieh¹⁷⁵, Tzu-Hsuan Huang¹⁷⁶, Junjie Huang¹⁵⁰, Salman Hussain¹⁷⁷, Sara Hyder¹⁵, Segun Ibitoye¹⁷⁸, Ehimario Igumbor¹⁷⁹, Olayinka Ilesanmi¹⁷⁸, Sumant Inamdar¹⁸⁰, Helen Ippolito¹¹³, Pooya Iranpour¹³³, Rana Irilouzadian³⁷, Seyed Sina Irvani³⁹, Nahlah Elkudssiah Ismail¹⁸¹, Chidozie Iwu¹¹³, Linda Merin J¹⁸², Hamed Jafari-Vayghan⁴⁷, Vardhmaan Jain²³, Chinwe Jaja¹⁸³, Spencer James¹⁸⁴, Tannaz Jamialahmadi¹³, Elham Jamshidi⁶⁷, Umesh Jayarajah¹⁸⁵, Shubha Jayaram¹⁸⁶, Ranil Jayawardena¹⁸⁵, Panniyammakal Jeemon¹⁸⁷, Bijay Jeswani¹⁸⁸, Har Ashish Jindal¹⁸⁹, Jost Jonas¹⁹⁰, Abel Joseph²³, Charity Joshua⁹¹, Jacek Jozwiak¹⁹², Se Yong

Jung¹⁰⁵, Ali Kabir³⁷, Robel Kabthymmer¹⁹³, Vidya Kadashetti¹⁹⁴, Sara Kamali Zonouzi¹⁶, Hyejung Kang¹⁰⁵, Tesfaye Kanko⁶⁶, Rami Kantar¹⁹⁵, Nitin Kapoor¹⁹⁶, Ibraheem Karaye¹⁹⁷, Amir Kasaeian³⁷, Altaseb Kassawu⁷⁷, Joonas Kauppila⁷⁹, Adane Kefale⁶², Azra Kenarkoohi¹⁴⁶, Andre Kengne¹⁹⁸, Esmā Kerboua¹⁹⁹, Pedram Keshavarz²⁰⁰, Mohammad Keykhaei¹⁶, Nastaran Khalili¹⁶, Daria Khaltourina²⁰¹, Yusra Khan²⁰², Moien Khan²⁰³, Muhammad Ali Khan²⁰⁴, Young-Ho Khang²⁰⁵, Sameer Khasbage²⁰⁶, Moawiah Khatatbeh²⁰⁷, Amir Khater¹⁴⁰, Bardia Khosravi¹⁶, Thanh Kim¹³⁰, Min Seo Kim²⁰⁸, Daniel Gebrehawaria Kinfē¹²⁴, Hamid Reza Koohestani⁷⁰, Maksim Kornilov²⁰⁹, Karel Kostev²¹⁰, Yuvaraj Krishnamoorthy²¹¹, Deepa Kumar²¹², Vivek Kumar⁴², Gaukhar Kurmanova²¹³, Ambily Kuttikkattu²¹⁴, Carlo La Vecchia²¹⁵, Bagher Larijani¹⁶, Avula Laxmaiah²¹⁶, Thao Le²¹⁷, Hankil Lee²¹⁸, Sang-Woong Lee²¹⁹, Yeong Yeh Lee²²⁰, Samson Legesse²²¹, Kruiy Lim²²², Lee-Ling Lim²²³, Huixin Liu²²⁴, Yüewei Liu²²⁵, Chun-Han Lo²²⁶, Stefan Lorkowski²²⁷, Paulo Lotufo²²⁸, Stefan Ma²²⁹, Shilpashree Madhava Kunjathur²³⁰, Ata Mahmoodpoor¹⁴, Jamal Majidpoor²³¹, Alaa Makki²², Mohammad-Reza Malekpour¹⁶, Reza Malekzadeh¹⁶, Navid Manafi⁷⁶, Yasaman Mansoori¹³³, Lyn March²³², Miquel Martorell²³³, Winfried März²³⁴, Sahar Masoudi¹⁶, Varshil Mehta²³⁵, Ria Mehta²³⁶, Abraham Mekuria⁶¹, Alexios-Fotios Mentis²³⁷, Shahin Merat¹⁶, Alibek Mereke²³⁸, Tuomo Meretoja²³⁹, Muayad Merza²⁴⁰, Meiraf Meshesha¹⁹³, Keadnew Mihretie⁵⁴, Erkin Mirrakhimov²⁴¹, Mohammad Mirza-Aghazadeh-Attari¹⁴, Maryam Mobarakabadi²⁴², Hailye Mogessie¹²⁶, Jasem Mohamadi¹⁴⁶, Ashraf Mohamadkhani¹⁶, Faezeh Mohammadi³⁷, Abdollah Mohammadian-Hafshejani³⁶, Teroj Mohammed²⁴⁰, Archisman Mohapatra²⁴³, Farnam Mohebi¹⁶, Zeinab Mokhtari⁷¹, Mariam Molokhia²⁴⁴, Jalal Moludi²⁴⁵, Ahmed Montasir²⁴⁶, Mahmood Moosazadeh¹²², Ghobad Moradi²⁴⁷, Milad Moradi⁶⁷, Mostafa Moradi Sarabi⁶⁰, Nazgol Motamed-Gorji¹⁶, Jibrān Sualeh Muhammad²⁴⁸, Efrén Murillo-Zamora²⁴⁹, Sani Musa²⁵⁰, Mohammadreza Naghipour²⁵¹, Mukhammad David Naimzada²⁵², Sreenivas Narasimha Swamy¹⁸⁶, Zuhair Natto²⁵³, Maryam Nazemipour¹⁶, Tam Ngo¹³¹, Dang Nguyen²⁵⁴, Van Nguyen²¹⁷, Long Nguyen¹³¹, Binh Nguyen¹²⁰, Robina Niazi²⁵⁵, Luis Nieto²⁵⁶, Taxiarchis Nikolouzakīs²⁵⁷, Seyyed Mohammad Ali Noori²⁵⁸, Faezeh Norouzi⁷¹, Brice Nouthé²⁵⁹, Virginia Nuñez-Samudio²⁶⁰, Bogdan Oancea²⁶¹, Richard Ofori-Asenso¹²³, In-Hwan Oh²⁶², Olubunmi Oladunjoye²⁶³, Antonio Olivas-Martinez²⁶⁴, Emad Omer²⁶⁵, Bilcha Oumer⁶⁶, Jagadish Rao Padubidri²⁶⁶, Jagadish Rao Padubidri⁸⁶, Mohammad Taha Pahlevan Fallahy¹⁶, Seoyeon Park¹⁰⁵, Harsh Patel²⁶⁷, Shanti Patel²⁶⁸, Mona Pathak²⁶⁹, Ronit Patnaik¹³², Venkata Suresh Patthipati²⁷⁰, Rajan Paudel²⁷¹, Gayatri Pemmasani²⁷², Simone Perna²⁷³, Fanny Petermann-Rocha²⁷⁴, Hai Pham¹³¹, Vivek Podder²⁷⁵, Richard Pollok²⁷⁶, Ashkan Pourabhari Langroudi¹⁶, Makan Pourmasoumi²⁵¹,

Akram Pourshams¹⁶, Hossein Poustchi¹⁶, Akila Prashant²⁷⁷, Elton Prates²⁷⁸, Liliana Preotescu²⁷⁹, Ibrahim Qattee²³, Jianchao Quan²⁸⁰, Mohammad Rabiee²⁸¹, Dhruvil Radadiya²⁸², Amir Radfar²⁸³, Sima Rafiei¹⁵⁸, Alireza Rafiei¹²², Pavan Raghuram⁸⁶, Niloufar Rahnavard¹³, Nazanin Rajai⁴², Pradhun Ram²⁸⁴, Sudha Ramalingam²⁸⁵, Shakthi Kumaran Ramasamy²⁸⁶, Premkumar Ramasubramani²⁸⁷, Kiana Ramezanzadeh⁶⁷, Priyanga Ranasinghe¹⁸⁵, Huiying Rao²²⁴, Indu Ramachandra Rao⁸⁶, Sina Rashedi¹⁶, Mohammad-Mahdi Rashidi¹⁶, Atta Rehman³⁹, Andre Renzaho²⁸⁸, Nazila Rezaei¹⁶, Negar Rezaei¹⁶, Nicholas Roberts²⁸⁹, Jefferson Rodriguez²⁹⁰, Leonardo Roever²⁹¹, Gholamreza Roshandel²⁹², Paul Ryan²⁹³, Anas Saad²³, Mehdi Saberifirozi¹⁶, Bahar Saberzadeh-Ardestani¹⁶, Umar Saeed²⁹⁴, Sher Safi¹⁸¹, Maryam Sahebzamani²⁹⁵, Amirhossein Sahebkar¹³, Soumya Sahoo²⁹⁶, Km Saif-Ur-Rahman²⁹⁷, Saina Salahi²⁹⁸, Sarvenaz Salahi³⁷, Mohammad Salehi¹⁶, Sana Salehi²⁹⁹, Amir Salimi⁶⁷, Mehrnoosh Samaei³⁰⁰, Abdallah Samy³⁰¹, Juan Sanabria³⁰², Senthilkumar Sankararaman³⁰³, Pradosh Sarangi³⁰⁴, Mayank Sardana³⁰⁵, Chinmoy Sarkar²⁸⁰, Danish Iltaf Satti³⁰⁶, Maria Schmidt¹³⁵, Aletta Schutte³⁰⁷, Michaël Schwarzinger³⁰⁸, Sadaf Sepanlou¹⁶, Dewi Setyowati³⁰⁹, Seyedahmad Seyedalinaghi¹⁶, Allen Seylani³¹⁰, Sayed Mohammad Shafiee¹³³, Pritik Shah³¹¹,³¹², Mohammad Amin Shahrbafe⁶⁷, Amir Shahzadeh³¹⁰, Elaheh Shaker¹⁴¹, Ali Shamekh¹⁴, Mohammed Shannawaz³¹³, Amrollah Sharifi²⁹², Amir Masoud Sharifnia³¹⁴, Jun She³¹⁵, Ali Sheidaei¹⁶, Mahdi Sheikh¹⁶, Jeevan Shetty⁸⁷, Mika Shigematsu²⁷⁹, Min-Jeong Shin³¹⁶, Siddharudha Shivalli⁴⁶, Parnian Shobeiri¹⁴¹, Zahra Shokri Varniab¹⁶, Seyed Afshin Shorofi¹²², Tariq Siddiqi¹⁴⁷, Jasvinder Singh²⁰⁴, Paramdeep Singh²⁰⁶, Achintya Singh²³, Deepika Singhal³¹⁷, Smriti Sinha⁸⁶, Md Shahjahan Siraj²⁹⁷, Mekonnen Sisay⁶¹, Gholam Sivandzadeh¹³³, Madhava Sai Sivapuram³¹⁸, Anna Skryabina³¹⁹, Eugene Sobngwi³²⁰, Amin Soheili³²¹, Amir Sohrabpour¹⁶, Ivan Soldatovic³²², Yonatan Solomon³²³, Melek Somai³²⁴, Houman Sotoudeh²⁰⁴, Rasoul Sotoudehmanesh¹⁶, Irem Soytutan Caglar²²⁹, Eleftherios Spartalis²³⁷, Saraswathy Sreeram⁸⁶, Cynthia Sukumar⁸⁶, Hafiz Ansar Rasul Suleria³²⁵, Dewi Suminar³²⁶,³²⁷, Keita Suzuki³²⁸, Majid Taheri³⁷, Urooj Tahir³²⁹, Ker-Kan Tan³³⁰, Nikhil Tandon²⁰⁶, Marcel Tanner³³¹, Seyed Mohammad Tavangar¹⁶, Solomon Techane¹⁹³, Freweni Tela²⁰, Mengistu Tequare²⁰, Berhe Tesfay³³², Getnet Teshome⁸⁸, Bhaskar Thakur³³³, Samar Tharwat³³⁴, Nikhil Thomas²⁸⁵, Bereket Tigabu³³⁵, Tala Tillawi³³⁶, Liz Toapanta-Yanchapaxi²⁶⁴, Domenico Trico³³⁷, Derara Tufa³³⁸, Fox Underwood³³⁹, Marco Vacante⁹¹, Seyed Mohammad Vahabi¹⁶, Rohollah Valizadeh³⁴⁰, Tommi Vasankari³⁴¹, Siavash Vaziri²⁴⁵, Georgios-Ioannis Verras³⁴², Giang Vu¹³¹, Song Wang³⁴³, Cong Wang³⁴⁴, Adisu Weldesenbet⁶¹, Brhane Welegebrial⁵⁷, Andrea Werdecker³⁴⁵, Nuwan Wickramasinghe³⁴⁶, Samuel Wiebe³³⁹, Beshada Woldegeorgis³⁴⁷, Grant Wyper³⁴⁸, Yang Xia¹⁷⁵, Suowen Xu³⁴⁹,

Ayalnesh Yalew³⁵⁰, Melaku Yalew⁷⁷, Jia Yang³⁵¹, Fereshteh Yazdanpanah¹⁴, Henock Yebyo³⁵², Yordanos Yeshitila⁶⁶, Ebrahim Yimer⁷⁷, Bacha Yohannes³⁵³, Chuanhua Yu³⁵⁴, Ismaeel Yunusa³⁵⁵, Farbod Zahedi Tajrishi¹⁶, Mohd Zahid²⁰⁴, Mazyar Zahir⁶⁷, Hadi Zamanian³⁵⁶, Moein Zangiabadian⁶⁷, Meysam Zarezadeh¹⁴, Zelalem Zegeye²¹, Teklewoini Zemicheal¹²⁴, Zhi-Jiang Zhang³⁵⁴, Xiu-Ju Zhao³⁵⁷, Yimin Zhao³⁵¹

1. Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain, 2. EASL International Liver Foundation, Geneva, Switzerland, 3. Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain, 4. CUNY Graduate School of Public Health and Health Policy, New York, NY, USA, 5. Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA, 6. Organ Transplant Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia, 7. Metabolic Liver Research Program, I. Department of Medicine, University Medical Center, Mainz, Germany, 8. Respiratory Department, Hospital Universitario de la Princesa; School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain, 9. Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain, 10. School of Public Health, University of Haifa, Haifa, Israel, 11. Department of Gastroenterology, Tel-Aviv Medical Center, Tel-Aviv, Israel, 12. Department of Health Metrics Sciences, Department of Family Medicine, University of Washington, Seattle, WA, USA, 13. Mashhad University of Medical Sciences, 14. Tabriz University of Medical Sciences, 15. Pakistan Institute of Medical Sciences, 16. Tehran University of Medical Sciences, 17. Jahrom University of Medical Sciences, 18. North Khorasan University of Medical Sciences, 19. Johns Hopkins University, 20. Mekelle University, 21. Jimma University, 22. University of Sharjah, 23. Cleveland Clinic, 24. Alfaisal University, 25. Obafemi Awolowo University, 26. Danphe Care Pvt Ltd, 27. Arizona State University, 28. Saint Mark Hospital, 29. University of Lomé, 30. Mayo Clinic, 31. Rutgers University, 32. Institute of Economic Growth, 33. Department of Health Philippines, 34. University of Technology Sydney, 35. Shaqra University, 36. Shahrekord University of Medical Sciences, 37. Iran University of Medical Sciences, 38. COMSATS Institute of Information Technology, 39. Independent Consultant, 40. Duke University, 41. Hamad Medical Corporation, 42. Harvard University, 43. Mayo Clinic Foundation for Medical Education and Research, 44. Jackson State University, 45. Ateneo De Manila University, 46. London School of Hygiene & Tropical Medicine, 47. Arak University of Medical Sciences, 48. Saudi Food and Drug Authority, 49. Imam Abdulrahman Bin Faisal University, 50. Ministry of National Guard-Health Affairs, 51. University of Health and Allied Sciences, 52. Carol Davila University of

Medicine and Pharmacy, 53. George Washington University, 54. Bahir Dar University, 55. Mari State University, 56. United Nations Children's Fund (UNICEF), 57. Adigrat University, 58. Azad University Science and Research Branch, 59. The University of Lahore, 60. Lorestan University of Medical Sciences, 61. Haramaya University, 62. Debre Berhan University, 63. University of Liège, 64. Public Health Foundation of India, 65. Kwame Nkrumah University of Science and Technology, 66. Arba Minch University, 67. Shahid Beheshti University of Medical Sciences, 68. Rochester Regional Health, 69. University of Management and Technology, 70. Saveh University of Medical Sciences, 71. Isfahan University of Medical Sciences, 72. Tarbiat Modares University, 73. University of London, 74. National Institute of Cholera and Enteric Diseases, 75. National Institute of Public Health, 76. University of California Los Angeles, 77. Wollo University, 78. El Bosque University, 79. University of Oulu, 80. B.J. Medical College, 81. Mizan-Tepi University, 82. University of Auckland, 83. University of Arkansas, 84. Queen Elizabeth Hospital Birmingham, 85. Medical Governance Research Institute, Tokyo, Japan, 86. Manipal Academy of Higher Education, 87. Royal College of Surgeons in Ireland Medical University of Bahrain, 88. University of Gondar, 89. Babol University of Medical Sciences, 90. Gadjah Mada University, 91. University of Catania, 92. Nepal Health Research Council, 93. Ahvaz Jundishapur University of Medical Sciences, 94. Nazarbayev University, 95. University of Medicine and Pharmacy of Craiova, Romania, 96. Hospital Italiano de Buenos Aires, 97. University of St Andrews, 98. National Institute of Epidemiology, 99. Geisinger Health System, 100. Astana Medical University, 101. University of Warwick, 102. Datta Meghe Institute of Medical Sciences, 103. Universal College of Medical Sciences, 104. King Edward Medical University, 105. Yonsei University, 106. University College London, 107. Coventry University, 108. La Sapienza University, 109. University of Geneva, 110. Pontifical Catholic University of Chile, 111. University of Milan Bicocca, 112. University of Porto, 113. University of Washington, 114. The Peter Doherty Institute for Infection and Immunity, 115. King Saud bin Abdulaziz University for Health Sciences, 116. Western Norway University of Applied Sciences, 117. Kathmandu University, 118. Johns Hopkins University School of Medicine, 119. Hue University of Medicine and Pharmacy, 120. Duy Tan University, 121. Bill & Melinda Gates Foundation, 122. Mazandaran University of Medical Sciences, 123. Monash University, 124. Aksum University, 125. Atlanta Veterans Affairs Medical Center, 126. Madda Walabu University, 127. Center for Life Sciences Research, Bangladesh, 128. Institute of Post-Graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital, 129. Ministry of Health and Medical Education, 130. Pham Ngoc Thach

University of Medicine, 131. Nguyen Tat Thanh University, 132. University of Texas, 133. Shiraz University of Medical Sciences, 134. University of Oxford, 135. Federal University of Rio Grande do Sul, 136. University of Medical Sciences, Ondo, 137. Alexandria University, 138. Tanta University, Faculty of Medicine, 139. Egypt Center for Research and Regenerative Medicine (ECRRM), 140. Cairo University, 141. Non-Communicable Diseases Research Center (NCDRC), 142. National Cancer Institute, 143. Debre Tabor University, 144. Pasteur Institute of Morocco, 145. Rochester General Hospital, 146. Ilam University of Medical Sciences, 147. Dow University of Health Sciences, 148. American University of Beirut, 149. Aga Khan University, 150. The Chinese University of Hong Kong, 151. Cornell University, 152. Charité Medical University Berlin, 153. Medical Research Council Unit, The Gambia, 154. King Edward Memorial Hospital, 155. Wageningen University & Research, 156. Deakin University, 157. Shahid Sadoughi University of Medical Sciences, Yazd, Iran, 158. Qazvin University of Medical Sciences, 159. Neyshabur University of Medical Sciences, 160. Sanjay Gandhi Postgraduate Institute of Medical Sciences, 161. Indian Institute of Public Health, 162. Sana Institute of Higher Education, 163. Macquarie University, 164. University of Maryland, 165. Shiraz University of Medical Sciences, Shiraz, Iran, 166. Bangladesh Agricultural University, 167. Syiah Kuala University, 168. Utrecht University, 169. Ministry of Health and Family Welfare, 170. Utica University, 171. University of Bergen, 172. University of Tokyo, 173. Fasa university of medical sciences, 174. Shahid Motahari Hospital, 175. China Medical University, 176. University of California San Diego, 177. Masaryk University, 178. University of Ibadan, 179. University of the Western Cape, 180. University of Arkansas for Medical Sciences, 181. MAHSA University, 182. Dr. D. Y. Patil University, 183. Stellenbosch University, 184. Genentech, 185. University of Colombo, 186. Government Medical College, 187. Sree Chitra Tirunal Institute for Medical Sciences and Technology, 188. GCS Medical College, Hospital & Research Centre, 189. Ministry of Health & Family Welfare, 190. Institute of Molecular and Clinical Ophthalmology Basel, 191. National Open University, 192. University of Opole, 193. Dilla University, 194. Krishna institute of Medical Sciences Deemed to be University, 195. Nab'a Al-Hayat Foundation for Medical Sciences and Health Care, 196. Christian Medical College and Hospital (CMC), 197. Hofstra University, 198. Medical Research Council South Africa, 199. Pierre & Marie Curie Center, 200. The University of Georgia, 201. Federal Research Institute for Health Organization and Informatics of the Ministry of Health (FRIHOI) , 202. Jouf University, 203. United Arab Emirates University, 204. University of Alabama at Birmingham, 205. Seoul National University, 206. All India Institute of Medical Sciences, 207. Yarmouk University,

208. Samsung Advanced Institute for Health Sciences & Technology (SAIHST), 209. High School Economics, 210. IQVIA, 211. Employees' State Insurance Model Hospital, 212. Pharmaceutical Research Associates, 213. Al Farabi Kazakh National University, 214. Pushpagiri Institute of Medical Sciences and Research Centre, 215. University of Milan, 216. Indian Council of Medical Research, 217. University of Medicine and Pharmacy at Ho Chi Minh City, 218. Ajou University, 219. Gachon University, 220. University of Science Malaysia, 221. Ethiopian Public Health Institute, 222. Sihanouk Hospital Center of HOPE, 223. University of Malaya, 224. Peking University People's Hospital, 225. Sun Yat-sen University, 226. Kirk Kerkorian School of Medicine at UNLV, 227. Friedrich Schiller University Jena, 228. University of Sao Paulo, 229. Ministry of Health, 230. BGS Global Institute of Medical Sciences, 231. Gonabad University of Medical Sciences, 232. University of Sydney, 233. University of Concepcion, 234. Medical University of Graz, 235. West Middlesex University Hospital, 236. SevenHills Hospital, 237. National and Kapodistrian University of Athens, 238. Asfendiyarov Kazakh National Medical University, 239. Helsinki University Hospital, 240. University of Duhok, 241. Kyrgyz State Medical Academy, 242. Hamadan University of Medical Sciences, 243. GRID Council, 244. King's College London, 245. Kermanshah University of Medical Sciences, 246. TMSS Medical College, 247. Kurdistan University of Medical Sciences, 248. College of Medicine, University of Sharjah, 249. Mexican Institute of Social Security, 250. Ahmadu Bello University, 251. Guilan University of Medical Sciences, 252. Moscow Institute of Physics and Technology, 253. King Abdulaziz University, 254. University of South Florida, 255. International Islamic University Islamabad, 256. WellStar Atlanta Medical Center, 257. University Hospital of Heraklion, 258. Jundishapur University of Medical Sciences, 259. University of British Columbia, 260. Institute of Medical Sciences, 261. University of Bucharest, 262. Kyung Hee University, 263. Baylor College of Medicine, 264. Salvador Zubiran National Institute of Medical Sciences and Nutrition, 265. Ajman University, 266. Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India, 267. Ochsner Medical Center, 268. Yale University, 269. Kalinga Institute of Medical Sciences, 270. Advent Health, 271. Tribhuvan University, 272. State University of New York, 273. University of Bahrain, 274. Diego Portales University, 275. Tairunnessa Memorial Medical College and Hospital, 276. St George's University of London, 277. Jagadguru Sri Shivarathreeswara University, 278. Federal University of Minas Gerais, 279. National Institute of Infectious Diseases, 280. University of Hong Kong, 281. Amirkabir University of Technology, 282. University of Kansas, 283. University of Central Florida, 284. Emory University, 285. PSG Institute of

Medical Sciences and Research, 286. Loyola University Medical Center, 287. Mahatma Gandhi Medical College and Research Institute, 288. Western Sydney University, 289. Weill Cornell Medical College, 290. University of Antioquia, 291. Federal University of Uberlândia, 292. Golestan University of Medical Sciences, 293. University College Cork, 294. International Center of Medical Sciences and Research, 295. Rafsanjan University of Medical Sciences, 296. All India Institute of Medical Sciences, Bathinda, Punjab, India, 297. International Centre for Diarrhoeal Disease Research, Bangladesh, 298. Azad University of Medical Sciences, 299. University of Southern California, 300. Brown University, 301. Ain Shams University, 302. Marshall University, 303. University Hospitals Rainbow Babies & Children's Hospital, 304. Indian Institute of Technology Kharagpur, 305. University of Massachusetts Medical School, 306. Shifa College of Medicine, Shifa Tameer-e-millat University, 307. University of New South Wales, 308. University hospital of Bordeaux, France, 309. Universitas Airlangga, 310. National Institute of Health, 311. Rajiv Gandhi University of Health Sciences, 312. Bangalore Medical College and Research Institute, 313. Symbiosis International University, 314. Khomein University of Medical Sciences, 315. Fudan University, 316. Korea University, 317. Gmers Medical College and Civil Hospital, 318. Dr Pinnamaneni Siddhartha Institute of Medical Sciences and Research Foundation, 319. Pirogov Russian National Research Medical University, 320. University of Yaoundé I, 321. Semnan University of Medical Sciences, 322. University of Belgrade, 323. Dire Dawa University, 324. Imperial College London, 325. University of Melbourne, 326. A.C.S. Medical College and Hospital, 327. Airlangga University, 328. Kanazawa University, 329. Federal Ministry of Health, 330. National University of Singapore, 331. Swiss Tropical and Public Health Institute, 332. Ethiopian Public Health Association, 333. Texas Tech University Health Sciences Center, 334. Mansoura University, 335. Komar University of Science and Technology, 336. Oxford University, 337. University of Pisa, 338. Salale University, 339. University of Calgary, 340. Urmia University of Medical Science, 341. UKK Institute, 342. General University Hospital of Patras, 343. The First Affiliated Hospital of USTC, University of Science and Technology of China, 344. Vanderbilt University, 345. Federal Institute for Population Research, 346. Rajarata University of Sri Lanka, 347. Wolaita Sodo University, 348. Public Health Scotland, 349. University of Science and Technology of China, 350. St. Paul's Hospital Millennium Medical College, 351. Peking University, 352. University of Zürich, 353. Ambo University, 354. Wuhan University, 355. University of South Carolina, 356. Qom University of Medical Sciences, 357. Wuhan Polytechnic University

Presentation: none.

References

1. Ghevariya V, Sandar N, Patel K, et al. Knowing What's Out There: Awareness of Non-Alcoholic Fatty Liver Disease. *Front Med (Lausanne)*. 2014;1:4.
2. Lazarus JV, Mark HE, Villota-Rivas M, et al. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? *J Hepatol*. 2022;76(4):771–780.
3. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*. 2022;7(9):851–861.
4. Yüksel F, Türkkan D, Yüksel I, Kara S, Celik N, Samdancı E. Fatty liver disease in an autopsy series of children and adolescents. *Hippokratia*. 2012;16(1):61–65.
5. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. *Pediatrics*. 2006;118(4):1388–1393.
6. Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A. The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis. *PLoS One*. 2015;10(10):e0140908.
7. Huber Y, Schulz A, Schmidtman I, et al. Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population-Based Study in Germany. *Hepatol Commun*. 2022;6(6):1457–1466.
8. Nah EH, Cho S, Kim S, Chu J, Kwon E, Cho HI. Prevalence of liver fibrosis and associated risk factors in the Korean general population: a retrospective cross-sectional study. *BMJ Open*. 2021;11(3):e046529.
9. **Harris R, Harman DJ**, Card TR, Aithal GP, Guha IN. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. *Lancet Gastroenterol Hepatol*. 2017;2(4):288–297.
10. Huber Y, Boyle M, Hallsworth K, et al. Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates with Hepatic Inflammation. *Clin Gastroenterol Hepatol*. 2019;17(10):2085–2092.
11. Schattenberg JM, Lazarus JV, Newsome PN, et al. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. *Liver Int*. 2021;41(6):1227–1242.

12. GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Gastroenterol Hepatol.* 2020;5(3):245–266.
13. Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. *Clin Gastroenterol Hepatol.* 2019;17(4):748–755.
14. Kanwal F, Kramer JR, Mapakshi S, et al. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. *Gastroenterology.* 2018;155(6):1828–1837.
15. Sanna C, Rosso C, Marietti M, Bugianesi E. Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers. *Int J Mol Sci.* 2016;17(5):717.
16. Li L, Liu DW, Yan HY, Wang ZY, Zhao SH, Wang B. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. *Obes Rev.* 2016;17(6):510–519.
17. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. *Nat Rev Gastroenterol Hepatol.* 2013;10(6):330–344.
18. Younossi Z, Tacke F, Arrese M, et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. *Hepatology.* 2019;69(6):2672–2682.
19. Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol.* 2020;5(8):739–752.
20. Alexander M, Loomis AK, Fairburn-Beech J, et al. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. *BMC Med.* 2018;16(1):130.
21. Tomah S, Alkhouri N, Hamdy O. Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand? *Clin Diabetes Endocrinol.* 2020;6:9.
22. Rutter H, Savona N, Glonti K, et al. The need for a complex systems model of evidence for public health. *Lancet.* 2017;390(10112):2602–2604.
23. Lazarus JV, Anstee QM, Hagström H, et al. Defining comprehensive models of care for NAFLD. *Nat Rev Gastroenterol Hepatol.* 2021;18(10):717–729.
24. **Díaz LA, Fuentes-López E, Ayares G, et al.** The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas. *Lancet Gastroenterol Hepatol.* 2022;7(6):552–559.

25. Lazarus JV, Mark HE, Anstee QM, et al. Advancing the global public health agenda for NAFLD: a consensus statement. *Nat Rev Gastroenterol Hepatol*. 2022;19(1):60–78.
26. Lazarus JV, Mark HE, Colombo M, et al. A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. *Aliment Pharmacol Ther*. 2022;55(2):234–243.
27. United Nations. Transforming Our World: The 2030 Agenda for Sustainable Development. <https://sdgs.un.org/2030agenda>. 2015. Accessed: August 15, 2022.
28. Ramirez-Rubio O, Daher C, Fanjul G, et al. Urban health: an example of a "health in all policies" approach in the context of SDGs implementation. *Global Health*. 2019;15(1):87.
29. Ralston J, Cooper K, Powis J. Obesity, SDGs and ROOTS: a Framework for Impact. *Curr Obes Rep*. 2021;10(1):54–60.
30. United Nations Statistics Division. SDG Indicators. UNSD. <https://unstats.un.org/sdgs/indicators/indicators-list>. 2020. Accessed: August 15, 2022.
31. GBD 2019 Universal Health Coverage Collaborators. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396(10258):1250–1284.
32. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396(10258):1223–1249.
33. GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396(10258):1160–1203.
34. GBD 2017 SDG Collaborators. Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018;392(10159):2091–2138.
35. Kwon O-H, Hong I, Yang J, Wohn DY, Jung W-S, Cha M. Urban green space and happiness in developed countries. *EPJ Data Sci*. 2021;10(1):28.

36. Miura T, Nagai S, Takeuchi M, Ichii K, Yoshioka H. Improved Characterisation of Vegetation and Land Surface Seasonal Dynamics in Central Japan with Himawari-8 Hypertemporal Data. *Sci Rep.* 2019;9(1):15692.
37. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017 (GBD 2017) Cause, REI, and Location Hierarchies. <https://ghdx.healthdata.org/record/ihme-data/gbd-2017-cause-rei-and-location-hierarchies>. 2018. Accessed: August 15, 2022.
38. UNDP. Technical notes: calculating the human development indices. (2020). <chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://hdr.undp.org/sites/default/files/2021-22_HDR/hdr2021-22_technical_notes.pdf>.
39. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. *Hepatology.* 2018;67(1):123–133.
40. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol.* 2021;18(4):223–238.
41. Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. *J Hepatol.* 2017;67(4):829–846.
42. Kabisch, N. The Influence of Socio-economic and Socio-demographic Factors in the Association Between Urban Green Space and Health. In: Marselle M, Stadler J, Korn H, Irvine K, Bonn A. Biodiversity and Health in the Face of Climate Change. 2019. Springer, Cham.
43. Jennings V, Bamkole O. The Relationship between Social Cohesion and Urban Green Space: An Avenue for Health Promotion. *Int J Environ Res Public Health.* 2019;16(3):452.
44. GBD 2019 Diseases Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet.* 2020;396(10258):1204–1222.
45. Bigna JJ, Noubiap JJ. The rising burden of non-communicable diseases in sub-Saharan Africa. *Lancet Glob Health.* 2019;7(10):e1295–1296.

46. Kankeu HT, Saksena P, Xu K, Evans DB. The financial burden from non-communicable diseases in low- and middle-income countries: a literature review. *Health Res Policy Syst.* 2013;11:31.
47. Chaker L, Falla A, van der Lee SJ, et al. The global impact of non-communicable diseases on macro-economic productivity: a systematic review. *Eur J Epidemiol.* 2015;30(5):357–395.
48. Hill PS, Buse K, Brolan CE, Ooms G. How can health remain central post-2015 in a sustainable development paradigm? *Global Health.* 2014;10:18.
49. Bennett S, Glandon D, Rasanathan K. Governing multisectoral action for health in low-income and middle-income countries: unpacking the problem and rising to the challenge. *BMJ Glob Health.* 2018;3(Suppl 4):e000880.
50. Shepley M, Sachs N, Sadatsafavi H, Fournier C, Peditto K. The Impact of Green Space on Violent Crime in Urban Environments: An Evidence Synthesis. *Int J Environ Res Public Health.* 2019;16(24):5119.
51. Ju Y, Moran M, Wang X, et al. Latin American cities with higher socioeconomic status are greening from a lower baseline: evidence from the SALURBAL project. *Environ Res Lett.* 2021;16(10):104052.

HEP-22-2589

ACCEPTED

Table 1. List of indicators used to develop the fatty liver disease-Sustainable Development Goal (fatty liver disease-SDG) score.

Indicator	Indicator description	Source	Related SDG indicator	Group category
Child overweight	Prevalence of overweight in children aged 2–4 years (%)	GBD 2017	2.2.2	Negative
Child wasting	Prevalence of wasting in children younger than 5 years (%)	GBD 2017	2.2.2	Negative
NCD mortality	Age-standardised death rate due to cardiovascular disease, cancer, type 2 diabetes, and chronic respiratory disease in populations aged 30–70 years, per 100,000 population	GBD 2017	3.4.1	Negative
UHC service coverage index	Coverage of essential health services, as defined by the UHC service coverage index of nine tracer interventions and risk-standardised death rates or mortality-to-incidence ratios from 32 causes amenable to personal health care ^a	GBD 2017	3.8.1	Positive
Health worker density	Health worker density per 1000 population, by cadre and summed across cadres ^b	GBD 2017	3.c.1	Positive
Education	Age-standardised level of educational attainment for all ages 15–99	GBD 2020 preliminary analysis	4.1.2	Positive
Urban green space score	Logarithm of total vegetation index per capita ^c	Kwon et al.	11.7.1	Positive

^a32 causes amenable to personal health care included tuberculosis, diarrhoeal diseases, lower respiratory infections, upper respiratory infections, chronic respiratory diseases, diphtheria, whooping cough, tetanus, measles, maternal disorders, neonatal disorders, colon and rectum cancer, non-melanoma skin cancer, breast cancer, cervical cancer, uterine cancer, testicular

cancer, Hodgkin lymphoma, leukaemia, rheumatic heart disease, ischaemic heart disease, cerebrovascular disease, hypertensive heart disease, peptic ulcer disease, appendicitis, hernia, gallbladder and biliary diseases, epilepsy, diabetes, chronic kidney disease, congenital heart anomalies, and adverse effects of medical treatment.

^bCadres included physicians, nurses and midwives, and pharmacists.

^cUsed the normalised difference vegetation index as a basis for the urban green space indicator.

Global Burden of Disease (GBD); non-communicable disease (NCD); universal health coverage (UHC).

ACCEPTED

Figure 1. Fatty liver disease-Sustainable Development Goal (fatty liver disease-SDG) framework. The fatty liver disease-SDG framework shows the SDG targets and indicators that are most relevant to fatty liver disease. The eight coloured segments indicate the selected targets and the seven selected indicators are nested within five of these targets. Solid lines indicate targets with a direct link to fatty liver disease and dashed lines show those indirectly related to fatty liver disease. NAFLD, non-alcoholic fatty liver disease; NCD, non-communicable disease.

HEP-22-2589
Figure 1. Fatty liver disease-Sustainable Development Goal (fatty liver disease-SDG) framework. The fatty liver disease-SDG framework shows the SDG targets and indicators that are most relevant to fatty liver disease. The eight coloured segments indicate the selected targets and the seven selected indicators are nested within five of these targets. Solid lines indicate targets with a direct link to fatty liver disease and dashed lines show those indirectly related to fatty liver disease. NAFLD, non-alcoholic fatty liver disease; NCD, non-communicable disease.




Figure 2. Geographical distribution of the fatty liver disease-Sustainable Development Goal (fatty liver disease-SDG) score, 2017.

A) Fatty liver disease-SDG score in 195 countries and territories developed by using six indicators (child wasting, child overweight, non-communicable disease mortality, a universal health coverage service coverage index, health worker density, and education attainment). B) Fatty liver disease-SDG score in 60 countries and territories developed by using the six aforementioned indicators plus the indicator urban green space (UGS). Countries with no colour indicate that they do not have UGS data. C) Percentage change (%) of the fatty liver disease-SDG score with or without the UGS indicator in 60 countries that have UGS data.

Percent change was calculated by first subtracting the fatty liver disease-SDG score developed without UGS from the fatty liver disease-SDG score developed with UGS, and then dividing the difference by the fatty liver disease-SDG score without UGS. Countries with no colour indicate that they do not have UGS data.

NAFLD, non-alcoholic fatty liver disease.

HEP-22-2589

Figure 2. Geographical distribution of the fatty liver disease-Sustainable Development Goal (fatty liver disease-SDG) score, 2017.

A) Fatty liver disease-SDG score in 195 countries and territories developed by using six indicators (child wasting, child overweight, non-communicable disease mortality, a universal health coverage service coverage index, health worker density, and education attainment). B) Fatty liver disease-SDG score in 60 countries and territories developed by using the six aforementioned indicators plus the indicator urban green space (UGS). Countries with no colour indicate that they do not have UGS data. C) Percentage change (%) of the fatty liver disease-SDG score with or without the UGS indicator in 60 countries that have UGS data. Percent change was calculated by first subtracting the fatty liver disease-SDG score developed without UGS from the fatty liver disease-SDG score developed with UGS, and then dividing the difference by the fatty liver disease-SDG score without UGS. Countries with no colour indicate that they do not have UGS data.

NAFLD, non-alcoholic fatty liver disease.

A)






Figure 3. Temporal trend of the fatty liver disease-Sustainable Development Goal (fatty liver disease-SDG) score by Global Burden of Disease super-region, 1990-2017. Fatty liver disease-SDG score ranges from 0 to 100. The lines represent the population-weighted average of scores for countries within each super-region.

HEP-22-2589
Figure 3. Temporal trend of the fatty liver disease-Sustainable Development Goal (fatty liver disease-SDG) score by Global Burden of Disease super-region, 1990-2017. Fatty liver disease-SDG score ranges from 0 to 100. The lines represent the population-weighted average of scores for countries within each super-region.



ACCEPTED

Figure 4. Comparisons of the fatty liver disease-Sustainable Development Goal (fatty liver disease-SDG) score to the A) Non-alcoholic fatty liver disease (NAFLD) preparedness score and B) Human Development Index (HDI) by Global Burden of Disease super-region. The fatty liver disease-SDG score, NAFLD preparedness score and HDI range from 0 to 100. The dots represent the population-weighted average of scores for countries within each super-region.



ACCEPTED